Skeletal muscle wasting and weakness are common complications associated with admission to the intensive care unit (ICU), with the loss of muscle mass and function increasing mortality and contributing to physical impairments post-discharge. While our understanding of the pathophysiology of this condition, commonly termed ‘ICU-acquired weakness’ (ICU-AW), has advanced considerably, no effective therapies are available. ICU-AW broadly encompasses a range of muscle-related impairments in this setting, including, but not limited to, critical illness myopathy and sepsis-induced myopathy. Pre-clinical models of critical illness can provide insights into the mechanisms underlying muscle wasting and weakness. Cell culture systems can provide mechanistic interrogation, by isolating effects to skeletal muscle directly. Small animal models, like rats and mice, allow for mechanistic investigation of ICU-AW using genetic models and testing pharmacological interventions. Larger animal models, including pigs and sheep, facilitate repeated blood and tissue sampling and can more closely recapitulate the standard-of-care within ICU settings. Although animal models can be advantageous for scientific investigation, they also have important limitations. Barriers to developing effective interventions include difficulty in obtaining muscle biopsies from patients, translating experimental findings between animal models and humans and replicating aspects of different ICU settings. This review explores the advantages and shortcomings of different pre-clinical models of critical illness, identifies gaps in understanding muscle wasting and weakness in critical illness and provides recommendations for improving the translation of therapeutics to promote functional recovery for patients post-discharge.

Up to 50% of patients admitted to the intensive care unit (ICU) experience a loss of muscle mass and function [1], which compromises muscle health and contributes to poor functional recovery post-discharge [2–5]. This phenomenon, first described by William Osler in 1892, as a ‘rapid loss of flesh’ in patients with sepsis [6], is now referred to as ICU-acquired weakness (ICU-AW) [7,8]. ICU-AW has been defined as ‘a syndrome of neuromuscular dysfunction acquired in the absence of causative factors other than the underlying critical illness and its treatment’ [9]. Although understanding of this syndrome has advanced considerably, its aetiology remains to be elucidated.

Patients with ICU-AW can experience an ~20% reduction in quadriceps muscle thickness within 10 days of admission to the ICU [10,11], a decrease of ~2% per day [12]. The extent of weakness is associated with both the severity of critical illness and the degree of systemic inflammation [1]. Patients with ICU-AW can experience chronic disability and reduced quality of life post-discharge [13]. ICU patients can also experience a mortality rate of up to 40% within five years post-discharge [14,15]. Despite the significant impact on health and quality of life, no therapeutics are currently available, with clinical interventions limited to minimising risk factors, such as disuse, and use of neuromuscular blocking agents. An incomplete understanding of the underlying pathophysiology makes ICU-AW difficult to prevent or treat. Appropriate models can provide meaningful insights into the pathophysiology of muscle wasting and weakness associated with critical illness, but barriers exist for clinical translation of these models and the development of effective treatments. To understand these issues, this review will explore the merits and shortcomings of different models of muscle wasting and weakness relevant to critical illness and provide recommendations for improving therapeutic translation. The pathophysiology of ICU-AW will not be discussed in detail since it has been reviewed comprehensively elsewhere [8].

The risk of developing ICU-AW increases when patients remain in the ICU for extended periods [16,17]. The current diagnostic method for ICU-AW uses the Medical Research Council (MRC) scale to assess muscle strength. First published in 1943 [18], this method assesses individual muscle strength on a scale of 0–5, with the score determined based on the expected strength of that muscle group [18]. Patients are diagnosed with ICU-AW if they have an MRC sum score of <48 or when the mean score of the 12 muscle groups measured on this scale is less than 4, indicating reduced muscle strength [9,17]. To prevent the progression of ICU-AW and to maintain muscle mass and strength after discharge from the ICU, accurate early-diagnostic methods are required, especially the development of biomarkers that are reliable and minimally invasive.

Other clinical measurements typically utilised in research environments include the assessment of muscle thickness (including the diaphragm), via bedside ultrasound [19,20], and hand grip strength [21]. More invasive measurements include histological assessment of muscles including, but not limited to, the vastus lateralis [11,22,23] and the diaphragm [24]. While specimens obtained via biopsy are highly valuable, collection of a sufficient quantity for conducting relevant assays is not always feasible. Furthermore, muscle samples comprising >150 fibres per sample are required for more accurate cross-sectional area (CSA) analyses [25]. At the whole-body level, functional capacity is typically measured using standardised surrogates such as the six-minute walk test [3] and activities of daily living (ADL) surveys [4]. Integration of these measurements could increase diagnostic capacity, but the requirement for additional labour may not be feasible for all ICUs.

Admission reason, organ failure and inflammation

Critical illness is a key determinant in developing ICU-AW. The severity of illness and inflammation is associated with the degree of impairment and weakness experienced by patients, with septic patients at greater risk of developing ICU-AW [1]. Excessive inflammation impairs muscle health and drives catabolism, contributing to wasting in critically ill patients [26,27]. High levels of systemic inflammation can also contribute to multi-organ dysfunction. The Sequential Organ Failure Assessment (SOFA) score determines the extent of organ failure, which is a well-documented risk factor for developing ICU-AW [11,28]. The SOFA score is specific to critical illness and predicts patient mortality in the ICU according to their level of organ failure [28], with the number of organs in failure being associated with the loss of mass of the rectus femoris muscle [11].

Disuse

Disuse leads to loss of muscle mass and function [29,30]. Without normal mechanical loading, muscle atrophies due to reduced muscle protein synthesis [31]. In the ICU, this unloading exacerbates the functional decline in patients [32] but is not the sole driver of muscle dysfunction. In a prospective study, after two weeks of immobilisation, patients with sepsis (n = 13) and age-matched healthy controls (n = 7; lower arm casting) experienced reduced muscle strength of the adductor pollicis muscle after a fatiguing protocol of supramaximal ulnar nerve stimulation [33]. However, unlike immobilised healthy controls, patients with sepsis also experienced reduced maximum strength with supramaximal ulnar nerve stimulation, highlighting the additional complexity and impact on muscle function associated with critical illness, compared with immobilisation alone.

Early mobilisation in ICU patients can be highly effective in attenuating weakness at discharge [34,35]. Exercise-based interventions are also effective in association with standard care. A 20-minute session of either passive or active leg cycling five days per week increased functional capacity (based on a six-minute walk test) and isometric quadriceps strength after hospital discharge [36]. However, cycle ergometry is not a feasible option for all patients. While current guidelines outline safety criteria for the mobilisation of patients, even for those that are mechanically ventilated [37], this is not always possible due to the severity of illness and because of staffing limitations [38,39]. Passive interventions like electrical muscle stimulation (EMS) to mimic exercise do not require mobilisation [40], but efficacy remains unclear based on the conflicting evidence presented in systematic reviews [41], and the variability in stimulation characteristics, including pulse and EMS duration [42].

Mechanical ventilation

Many patients admitted to the ICU are mechanically ventilated [43,44]. Prolonged mechanical ventilation can cause diaphragm weakness due to unloading of this tonically contracting muscle [45], causing delays for patients to be weaned from mechanical ventilation [46–48], which compromises health and increases mortality [44,49,50]. Mechanical ventilation is also independently associated with ICU-AW [51–56] and with an increased mortality in these patients [57].

Modification of patient care to address some of these factors has improved patient outcomes after discharge from the ICU. Neuromuscular blockers (NMBs) facilitate intubation in patients which can optimise mechanical ventilation [58], but since NMBs are competitive acetylcholine antagonists that bind to nicotinic receptors on the motor endplate, they prevent excitation of the muscle [59]. This can potentially exacerbate the effects of disuse, which is a known risk factor for ICU-AW. Use of these agents in the clinic has declined during the 21st century due to improvements in clinical practice and ventilatory support, thus limiting patient risk [58,60]. Isolating the direct effects of disuse/immobilisation from sedation, mechanical ventilation and NMBs, is difficult, but disuse in the absence of critical illness can cause significant muscle atrophy [29,30].

The diagnosis and pathophysiology of ICU-AW is made more complex by different risk factors, including age [61], sex [52] and nutrition status [62]. Heterogeneity within the patient population serves as a considerable barrier for elucidating the pathophysiology of ICU-AW and for the design of meaningful clinical studies. To overcome these barriers, it is imperative to understand the populations most at risk, for better patient stratification and for developing and refining pre-clinical models.

While current understanding of the risk factors that lead to muscle wasting and weakness relate to the typical ICU population, which is often patients of a more advanced age, further investigation is needed of the muscle wasting and weakness in younger patients (infants, children and young adults). Furthermore, accounting for differences between biological sex as a risk factor within these categories is essential for developing a more personalised standard of care for ICU patients to optimise their recovery.

Age

Sarcopenia, the loss of muscle mass with advancing age, contributes to frailty and the large burden of disease in the elderly [63]. A large proportion of patients admitted to the ICU are of advanced age and more likely to present with compromised muscle health, including sarcopenia, that contributes to adverse functional outcomes post-discharge [61].

While advanced age considerably affects susceptibility to ICU-AW, younger adults [64] and paediatric [65] patients still experience muscle wasting and weakness after ICU admission. Younger adult and paediatric patients are not typically included in longitudinal follow-up studies which may bias mechanistic investigations. Similarly, further clinical investigation into potential differences in the mechanisms of ICU-AW in paediatric, adult and aged populations is required to provide more targeted treatments and standard of care.

Sex

Women admitted to the ICU have significantly higher mortality rates [66], are at greater risk of developing ICU-AW [52,67,68] and experience greater reductions in the CSA of type IIA fibres in the vastus lateralis muscle compared with men [69]. Analysis of serum hormonal status in 37 post-menopausal women with ICU-AW revealed no hormonal dysfunction compared with patients without ICU-AW [68]. Despite these significant findings, population bias in these studies confounds the accuracy of their interpretation to the female sex. It is currently unknown whether women with a regular menstrual cycle are equally susceptible to ICU-AW as post-menopausal women. While studies in animal models of critical illness are limited, female mice exhibited a different wasting profile in response to disuse atrophy compared with male mice [70]. Female mice had an earlier onset of wasting in the tibialis anterior (TA) muscle, and greater overall reductions in type IIB fibre CSA compared with male mice over 168 hours of disuse [70]. As there were no experimental modulations of ovarian function (i.e. ovariectomy), it is unclear whether the changes were mediated by ovarian hormones. Further studies, without the confounding factor of age, i.e., in amenorrheic women under 50, are required to confirm and uncover the mechanisms underlying these reported sex-specific differences.

Malnutrition

Nutrition plays an important role in protein synthesis and is essential for muscle development, for preserving muscle mass and for promoting muscle regeneration [71]. Inadequate intake of protein and amino acids can exacerbate muscle atrophy, especially in patients with cancer cachexia [72], sarcopenia [73] and ICU-AW [62]. Patients are more likely to retain muscle mass with adequate nutrition in the first seven days of admission to the ICU compared with patients who do not achieve energy requirements [74]. Malnourished patients in the ICU had significantly decreased CSA of the pectoralis major muscle measured by CT scan compared with non-malnourished counterparts [75]. However, despite adequate feeding, critically ill patients can also have a blunted capacity for protein synthesis, termed ‘anabolic resistance’ [76]. Incorporation of phenylalanine labelled protein into the muscle was 60% lower in ICU patients compared with healthy controls, despite matched amino acid availability in the systemic circulation and similar rates of fasting myofibrillar protein synthesis [76]. Although adequate nutrition may not necessarily reverse the loss of muscle mass, it may help attenuate the severity of wasting and possible complications after hospital discharge.

Unlike the adult ICU population, the incidence of ICU-AW in the paediatric ICU (PICU; <18 years) is considerably lower, with reported cases between 0.02% and 1.7% [77,78]. Ultrasound measurements from 30 PICU patients revealed ≥10% loss of muscle mass of the lower limb and diaphragm occurring within five to seven days of admission [79]. Limited data for lower limb biopsies in three patients revealed ‘scattered basophilic atrophic fibres with loss of ATPase reactivity’ associated with loss of myosin and increased calpain activity, consistent with a diagnosis of acute quadriplegic myopathy [77]. Persistent weakness or altered endurance capacity was experienced by survivors 3–18 months after hospital discharge [77].

Within the PICU, older patients (more than ten years) were significantly more likely to develop ICU-AW, particularly after onset of puberty (5.1% incidence) compared with infants (three months to three years; 0.7% incidence) [77]. Older children (more than one year of age) were more likely to experience wasting of the lower limb compared with infants (less than one year old) [79].

There is currently an insufficient understanding of the pathophysiology, risk factors and long-term consequences on muscle function and development after critical illness in children [80]. The complexity in paediatric ICU-AW highlights the importance of further investigations into mechanisms associated with age and the onset of puberty, as well as long-term functional outcomes, regardless of age.

The mechanisms underlying inadequate recovery from ICU-AW remain poorly understood. Patients with ICU-AW are more susceptible to long-term skeletal muscle dysfunction after discharge [5,81], with physical impairments persisting for up to five [3] or ten years [82]. In a prospective, longitudinal cohort study, physical dysfunction was evident for up to five years after acute respiratory distress syndrome (ARDS), with patients only able to achieve 76% of their predicted functional capacity in the six-minute walk test [3]. The impaired recovery was despite an initial improvement at one year, after which patients reached a plateau in the restoration of muscle function. Survivors of severe sepsis also experienced long-term functional impairments based on their performance of ADL and instrumental ADLs surveys [4]. Long-term abnormalities (6–24 months) in motor and sensory nerve conduction were not attributed to a specific sub-population (based on age, gender, diagnosis of sepsis or time after ICU discharge) [83]. Despite reports of significant long-term dysfunction, more comprehensive longitudinal studies are required to better understand the trajectory of wasting and weakness in patients across different ages, sex and critical illness diagnoses.

Persistent muscle weakness and fatigue with ICU-AW are attributed to a poorly understood, heterogeneous skeletal muscle pathology [2,84]. Few clinical studies have investigated the mechanisms of long-term wasting and weakness. Six months after discharge, most patients showed improvements in muscle CSA measured via CT scan, but these were still lower than in age- and sex-matched controls [2]. Quadriceps muscle CSA did not correlate with muscle strength, based on isometric peak torque measurements [2]. The same study examining vastus lateralis muscle samples revealed that patients who did not exhibit a restoration of muscle mass had reduced satellite cell (muscle stem cell) content, possibly indicative of impaired muscle regenerative capacity and poor muscle health [2]. Comorbidities may also be a significant risk factor for some, but not all patients experiencing long-term dysfunction [2]. Extrapolation of these results from these studies is limited due to the small sample size (11–15 patients). Furthermore, very few studies investigate the efficacy of tailored intervention programmes to enhance recovery using adequate control groups [85]. Most longitudinal follow-up studies investigate patients during mid-life or older, with few studies including younger adults and children. Further mechanistic investigation into long-term functional outcomes is required.

ICU-AW and long-term functional impairments carry a high burden of disease and severely affect the quality of life for patients [86]. Despite the magnitude of these long-term deficits, few studies have evaluated the mechanisms responsible for persistent muscle dysfunction. This dearth of knowledge is attributed to the high rates of attrition post-hospital discharge [87] and because most studies focus on the initial insult of disease, such as sepsis, rather than the long-term consequences after the life-threatening critical illness has resolved. Further investigation into risk factors and mechanisms relating to age and sex stratification is needed to better inform patient care.

Despite a reasonable understanding of the various causative factors for ICU-AW, treatment efficacy is limited. Although a greater mechanistic understanding of the syndrome could be achieved from muscle biopsies obtained from patients, such studies are limited by logistical challenges, including the need for sufficient sample sizes for statistical power and meaningful physiological analyses. The collection of diaphragm muscle biopsies, although desirable for such mechanistic investigations, is obviously technically challenging because of its anatomical location and function.

There are clear gaps in our understanding of critical illness and ICU-AW that could be addressed through the development, optimisation and use of cell and animal models. These include [1] identifying the mechanisms underlying muscle wasting and weakness in critical illness relevant to ICU-AW; [2] identifying effective nutritional, pharmacological and other interventions (including exercise and electrical stimulation) that can counter muscle loss and physical dysfunction associated with critical illness; [3] identifying whether some muscle groups are more susceptible to weakness and wasting in critical illness, including comparisons between limb muscles and the diaphragm; and [4] identifying whether there are age and sex-specific differences with respect to the susceptibility to muscle dysfunction during critical illness and recovery post-discharge from the ICU. To understand the origins of these gaps in knowledge and to address these barriers to improve treatment efficacy, rigorous pre-clinical investigations in critical illness settings are important for evaluating therapeutic potential. Cell and animal models may provide greater mechanistic insights applicable to specific clinical settings, mindful of their obvious limitations. This review describes the advantages and limitations of some of the models employed in pre-clinical studies of critical illness relevant to ICU-AW and provides suggestions for improving clinical translation.

Pre-clinical animal models of critical illness can control for risk factors such as age, sex and disease co-morbidities, reducing genetic variability and increasing statistical power. Compared with in vitro cell culture models (described in detail later), experimental animals facilitate investigation of intact physiological systems and their interactions. Small animals, like rats and mice, allow for greater mechanistic investigation of specific aspects of critical illness relevant to ICU-AW through genetic and pharmacological manipulations. Larger animals, including pigs and sheep [8,88], allow for repeated blood and tissue sampling and can more closely recapitulate the standard-of-care in ICU settings. Animal models also allow for examination of different muscle groups with different muscle fibre type composition, which may be relevant when describing treatment outcomes and potential clinical relevance. The strengths and limitations of the different models of muscle wasting associated with critical illness are summarised in Figure 1 [88,89].

Strengths and limitations of different models of muscle wasting and weakness relevant to critical illness.

Figure 1:
Strengths and limitations of different models of muscle wasting and weakness relevant to critical illness.

Muscle wasting and weakness with critical illness and intensive care unit (ICU) admission can be highly debilitating for patients, with significant impact on quality of life. Currently, there are no approved clinical treatments. Models of critical illness, including cell culture systems, and small and large animal models, provide experimental platforms for mechanistic interrogation and understanding how risk factors, such as age, sex and co-morbidities, contribute to an acquired myopathy. In vitro systems help isolate the effects of critical illness on skeletal muscle directly, providing excellent high-throughput screening of potential therapeutic candidates, despite lacking an integrated physiological system like in intact animal models. Small animals such as mice and rats are relatively cost-effective experimental platforms compared with larger animal models such as pigs and sheep, and their genome can be edited more easily for identifying specific genes in the conferral of protection from and/or susceptibility to wasting and weakness with critical illness. In contrast, larger animals have an immune system like that in humans with the capacity for more invasive monitoring and repeated blood and tissue sampling. *Although sheep are utilised for sepsis research, they are not commonly utilised for studying muscle wasting and weakness in critical illness. Ticks represent the disease phenotype induced in each of the different models, and crosses indicate these models are not commonly utilised for studying these conditions. Created in BioRender. Bongetti, A. (2025) https://BioRender.com/.

Figure 1:
Strengths and limitations of different models of muscle wasting and weakness relevant to critical illness.

Muscle wasting and weakness with critical illness and intensive care unit (ICU) admission can be highly debilitating for patients, with significant impact on quality of life. Currently, there are no approved clinical treatments. Models of critical illness, including cell culture systems, and small and large animal models, provide experimental platforms for mechanistic interrogation and understanding how risk factors, such as age, sex and co-morbidities, contribute to an acquired myopathy. In vitro systems help isolate the effects of critical illness on skeletal muscle directly, providing excellent high-throughput screening of potential therapeutic candidates, despite lacking an integrated physiological system like in intact animal models. Small animals such as mice and rats are relatively cost-effective experimental platforms compared with larger animal models such as pigs and sheep, and their genome can be edited more easily for identifying specific genes in the conferral of protection from and/or susceptibility to wasting and weakness with critical illness. In contrast, larger animals have an immune system like that in humans with the capacity for more invasive monitoring and repeated blood and tissue sampling. *Although sheep are utilised for sepsis research, they are not commonly utilised for studying muscle wasting and weakness in critical illness. Ticks represent the disease phenotype induced in each of the different models, and crosses indicate these models are not commonly utilised for studying these conditions. Created in BioRender. Bongetti, A. (2025) https://BioRender.com/.

Close modal

Models of sepsis

Sepsis is a leading cause of ICU admission and mortality worldwide [90] and an independent risk factor for developing ICU-AW [1]. Many inflammatory models can lead to multi-organ dysfunction and/or failure [91,92], which are predictive factors for ICU-AW [11,52,86]. Various models of sepsis have provided important information about the time course of sepsis development [93] and are key to investigating the mechanisms responsible for muscle wasting and weakness in patients with sepsis.

a) Caecal ligation and puncture

The caecal ligation and puncture (CLP) procedure, a model of polymicrobial sepsis, involves the isolation, ligation (distal to the ileocaecal valve) and puncture of the caecum via laparotomy [94–96]. The severity of the CLP model depends on the length of the ligation, size and number of punctures, and whether antibiotics are administered [94–96]. CLP is often described as the ‘gold standard’ of small animal (rodent) models of sepsis, as it closely resembles the progression of sepsis in humans [96]. Administration of antibiotics, analgesics and fluid resuscitation in these models can resemble the standard of care received by patients in the ICU.

In rodents, the CLP model can lead to significant reductions in body mass, muscle mass and muscle function [97–100]; a skeletal muscle phenotype often exhibited by critically ill patients. Generally, muscle mass loss is evident as early as 24 hours post CLP surgery in mice [101] and at 96 hours [100], 5 days [102,103] and 7 days [98]. Variations in model severity mean that comparisons between studies are not always seamless, with differences in mortality rates and severity of sepsis, endpoint and muscle groups analysed. Even considering these differences, the CLP model is highly informative, especially when making comparisons between studies. As with sepsis in patients, increased muscle protein catabolism and reduced protein synthesis have also been observed in mice, rats and pigs using this model [101,104–106]. Although the CLP model in pigs is highly effective and offers considerable advantages as a model system, including its greater immune system capacity and provision for invasive monitoring and repeat blood collection, rodents are utilised more commonly because they are more cost effective and require less direct researcher support.

In patients, sepsis-induced myopathy is associated with reduced muscle function. In septic mice, five days post CLP surgery, electromyography (EMG) of the sciatic nerve-gastrocnemius muscle complex revealed a significantly increased amplitude, with signs of axonal swelling compared with controls [99]. However, both indirect nerve stimulation and direct muscle stimulation of the extensor digitorum longus (EDL) muscle revealed impaired maximum absolute force generating capacity in septic mice, indicating that effects intrinsic to the muscle were responsible for the dysfunction rather than neural abnormalities [99]. Animals in this study were six months of age, older than those typically used in sepsis research (10–12 weeks), which increases translational relevance to adult populations. However, these studies would benefit from examining differences in aged mice (>18 months old) to examine how sepsis affects muscle health in the elderly, especially with respect to neuromuscular dysfunction. Experiments on isolated single EDL muscle fibres to interrogate mechanisms pertaining to reduced functional capacity showed that contractile dysfunction in septic mice was not attributed to aberrant Ca2+-handling but to sarcomere disorganisation, with muscle fibres being more susceptible to damage even when subjected to a protocol of passive stretching [99]. Using rodents in sepsis research allows for the assessment of muscle function either in situ with nerve and blood supply intact or ex vivo on isolated muscles, facilitating investigation of neuromuscular mechanisms in ways that cannot be replicated in patients. Septic rats exhibited altered sodium channel properties, 10 days after CLP surgery [107], and fibres isolated from the flexor digitorum brevis muscle had reduced maximum sodium current and sodium conductance, indicative of muscle inexcitability [107].

Time course analysis of wasting in the tibialis anterior muscles of mice after CLP surgery revealed an initial increase in local inflammatory signalling and ubiquitin-dependent catabolic processes 24 hours and 96 hours post sepsis induction [100]. A more comprehensive analysis of wasting (12, 24, 48 and 72 hours) after CLP identified three specific transcriptional phases: inflammatory-immune (0–12 hours), inflammatory-atrophy (24 hours) and atrophy (48–72 hours) [108], revealing important insights into the initiation of muscle wasting with sepsis. Given that analyses were limited to one muscle group [108], it is possible that different muscles with different fibre type compositions may be affected differently by sepsis. Identifying potential muscle/fibre type specific responses to sepsis could help inform therapeutic development.

Genetic manipulations in mouse models provide advantages for interrogating the mechanisms of disease. Muscle-specific deletion of Il6st revealed the importance of gp130/JAK2/STAT3 signalling in mediating muscle wasting after CLP surgery, with a partial attenuation of wasting in the tibialis anterior and gastrocnemius/plantaris muscle complex compared with wildtype (WT) CLP counterparts 96 hours post-surgery [100]. Genetic ablation of muscle stem cells (satellite cells) impaired recovery of muscle fibre size in tibialis anterior muscles 30 days after CLP surgery [109], which coincided with a blunted capacity for CLP mice to recover from a secondary muscle injury (induced by intramuscular injection of barium chloride) even four weeks post damage [109]. These studies investigating the role of muscle stem cells in recovery from sepsis-induced muscle wasting are important for understanding why many older patients in the ICU experience a decline in muscle health, attributed potentially to an age-related impairment in regenerative capacity [110]. Studies using older (rather than young or adult) mice age would likely yield greater mechanistic insight into the muscle wasting and weakness in critically ill older adults, who make up a large proportion of the ICU patient population.

The CLP model has been described as the ‘gold standard’ small animal (rodent) model of sepsis because it closely resembles the progression of sepsis in humans [96] and has been very well characterised. However, despite the widespread use of the CLP model, it is not a model of severe, chronic sepsis and is not typically suitable for long-term studies because it is associated with a high mortality. Studies incorporating antibiotics and fluid resuscitation interventions with the CLP model report considerably lower mortality rates, with animals surviving for up to 50 days after CLP surgery [109]. Differences in the severity and duration of the various models need to be considered when interpreting different study findings. Another important consideration for this model is that the consequences from CLP have their origins in the peritoneal cavity, which, although clinically relevant, since ~21% of septic patients present to the ICU with some form of peritonitis [111], the aetiology differs from the majority of patients.

b) Administration of live bacteria

A common method of inducing sepsis in small [112] and large animal models [113,114] is the administration of an intraperitoneal (i.p) or intravenous (i.v) bolus or infusion of bacteria, either, in mice [115,116], rats [117], pigs [118,119], sheep [113,120], dogs [121] and non-human primates, such as baboons [122]. Rodents and pigs are the most employed models for studying the relationship between sepsis and skeletal muscle wasting and weakness [112,123,124]. Muscle atrophy has been observed 7 and 14 days after administration of Escherichia coli to rats [112], which was associated with reduced maximum tetanic force (strength) of the tibialis cranialis muscle in situ, not attributed to a change in the number of acetylcholine receptors [112]. Although this suggests a potential intrinsic deficit in muscle function, closer interrogation of the neuromuscular dysfunction would be required to be definitive.

Studies utilising administration of E. coli are typically of longer duration than CLP models, which are usually terminal seven days after induction of sepsis. A longer time course resulting in muscle wasting for investigation of prolonged deficits in muscle mass and function, like those in many patients who are in the ICU for extended periods. Furthermore, i.v. administration of E. coli allows for investigation of muscle wasting and weakness associated with sepsis originating within the systemic circulation, which is more clinically relevant than many other sepsis models where the effects of critical illness originate in the peritoneal cavity.

Intranasal delivery of Streptococcus pneumoniae [125] provides an alternative induction route of sepsis, utilising the less common gram-positive sepsis with origins in the lungs, an induction method highly relevant to patients that present with respiratory-derived sepsis (~70% of septic patients) [111]. Delivery via this method in mice induced diaphragm muscle weakness after five days, evident from the decrease in maximum force production of isolated diaphragm muscle strips ex vivo [125]. There was no change in forelimb grip strength over the study duration, but assessments of muscle size or hindlimb muscle function were not conducted. Further investigations of muscle structure–function are needed to properly assess its merits as a model of critical illness and relevance to ICU-AW.

Although bacterial administration is a reliable method for investigating the host response to infectious mediators, bacterial strains do not typically replicate in vivo. Large doses of bacteria are typically required to overcome host defence mechanisms [126] and initiate an aberrant inflammatory response. Furthermore, studies in animal models commonly require a continual infusion of bacteria, rather than a bolus administration, which does not recapitulate the induction of sepsis in patients [112], and limits their clinical translation.

c) Faecal (caecal) slurry

Sepsis can also be induced through the harvesting of material found in the large intestine, termed a faecal or caecal slurry (CS). In these cases, the contents of the bowel are combined with saline and other reagents, such as glycerol, to create a suspension or slurry of known concentration, which is then injected (i.p.) into either mice [127], rats [128] or pigs [129]. Atrophy of the tibialis anterior muscles and reduced forelimb grip strength have been reported in mice up to 61 days post-injection [130], with wasting attributed to increased neutrophil infiltrate 14 days after CS injection. Neutrophil-specific depletion using Ly6G antibody increased forelimb grip strength and muscle CSA compared with CS injection alone, confirming the essential role of neutrophils in muscle wasting with critical illness. Unlike other sepsis models in mice, the survivability of mice for up to three months after sepsis induction allows for investigation of a muscle wasting phenotype like that in patients hospitalised for extended periods. This model has also been utilised in other model organisms, with nitric oxide overproduction and mitochondrial dysfunction (complex I inhibition and ATP depletion) evident in skeletal muscles of rats [131]. Electrophysiological abnormalities have also been reported in this model, with reports of membrane depolarisation and sodium channel inactivation in the muscles of pigs [132].

Studies in rats and pigs have yet to associate the induction of sepsis with muscle wasting and weakness in the CS model, and mice remain the preferred species for assessment due to the comprehensive testing that can be undertaken. Studies in mice are also advantageous as they permit investigations relevant to long-term dysfunction after ICU discharge. One month after CS injection, mice experienced a loss of intrinsic or specific force (maximum strength normalised to muscle cross-sectional area), in isolated EDL muscles ex vivo, without the loss of muscle mass [133]. Ankle plantar flexion peak torque (assessed in vivo) remained compromised for up to 70 days after sepsis induction [134], despite resolution of systemic inflammation. The impaired muscle strength was attributed to a reduced abundance of mitochondrial respiratory chain complexes, I, II and IV [133].

Although proposed as an alternative to CLP because of its less invasive methodology, limitations of the CS model include the inability to standardise microbial type and concentration, making its severity and mortality outcomes difficult to reproduce. Attempts to refine the variability in the model have been proposed elsewhere [135].

Despite the restoration of muscle mass, the CS model is one of the first models of long-term dysfunction [133,134] and the capacity to interrogate mechanisms underlying muscle wasting and weakness in the long term after critical illness is particularly advantageous. The long-term CS model also offers potential for testing novel therapeutics in settings relevant to patients in the ICU.

Other models of sepsis not used for studying muscle wasting and dysfunction

Other animal models for studying the progression of sepsis and associated treatments include colon ascendens stent peritonitis (CASP), implantation and abscess models, although these are not typically employed for studying sepsis-induced muscle wasting and weakness. Investigations of the skeletal muscle phenotype in these models would help determine their suitability for studying muscle dysfunction in settings of critical illness. The CASP model was developed to standardise sepsis in animal systems [136]. In mice or rats, it involves a similar midline laparotomy like in the CLP model, followed by insertion of a stent into the ascending colon, allowing faecal contents to flow into the peritoneum, resulting in sepsis [137]. Mortality is controlled through regulation of stent diameter. Unlike the CLP procedure, CASP involves a constant leakage of bowel contents into the peritoneal cavity, causing ongoing infection, compared with intra-abdominal abscess formation in the CLP model [126].

While most models of sepsis are either polymicrobial or utilise gram-negative bacteria, the fibrin clot implantation model allows for investigation of gram-positive sepsis. The fibrin clot is impregnated with Staphylococcus aureus and placed into the peritoneal cavity in mice after a small laparotomy [138]. Similar models involving implantation include wicks containing faecal material embedded into the thigh muscle in dogs [139,140], and formation of a dermal abscess in rats after implantation of Pseudomonas aeruginosa underneath a skin graft [141,142]. Staphylococcus aureus can also be placed into the lower lobe of the lung to induce sepsis [143]. This model, combined with mechanical ventilation, is used for studying sepsis with origins in the lungs (pneumonia), which is a common site of infection in patients. It is unclear whether these models exhibit a muscle wasting phenotype, but they could provide insight into muscle pathologies associated with septic insults from various origins.

Models of sterile inflammation and endotoxemia

Since high levels of inflammation in critically ill patients are associated with ICU-AW, different models of inflammation are used to study the pathophysiology of ICU-AW (Figure 1) [26,27]. Sterile inflammation, induced by pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) or zymosan, activates Toll-like receptors (TLRs) and can mimic the systemic inflammation associated with sepsis [144]. Typically administered i.p. or i.v. to model organisms, these serve as good platforms for studying the acute inflammatory response associated with infection (Table 1) [126]. Isolation of the toxin allows for standardisation of the inflammatory response, which is more difficult with polymicrobial and live-inoculation bacterial models. Furthermore, the sterile nature of the PAMP allows for their use in cell culture systems to mechanistically interrogate the inflammatory response and the cellular responses to therapeutic interventions.

Table 1
Models of muscle wasting and weakness associated with critical illness.
Animal/ Cell typePathology induced
(administration route)
Welfare supportSkeletal muscle phenotypeClinical phenotype and translational weaknessesRef.
StrengthsWeaknesses
Caecal ligation and puncture (CLP
Mice Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, antibiotics and analgesic optional 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased protein catabolism

  • Reduced protein synthesis

  • Disorganised sarcomeres

  • Anabolic resistance

 
  • Sepsis progression similar to humans

  • ICU-like standard care

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[98–101,145,146
Rats Sepsis; poly-microbial
(surgical) 
Fluid resuscitation and analgesic optional 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased protein catabolism

  • Reduced protein synthesis

  • Disorganised sarcomeres

  • Hypoexcitability

 
  • Sepsis progression similar to humans

  • ICU-like standard care

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Nerve pathology

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[104,105,107
Pigs Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, haemodynamic maintenance, analgesic and anti-inflammatories 
  • Muscle atrophy

  • Increased protein catabolism

  • Reduced protein synthesis

 
  • ICU-like standard of care

  • Loss of mass

  • Altered protein balance

  • Repeat blood sampling

  • Immune system similarity to humans

 
  • No mechanical ventilation or immobilisation

  • Cost prohibitive

  • Labour intense

 
[106
Inoculation with live bacteria 
Mice Sepsis; Escherichia coli
(i.p.) 
Limited 
  • Muscle atrophy

 
  • Loss of mass

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[147
Rats Sepsis; Escherichia coli
(i.p., i.v.) 
Limited 
  • Muscle atrophy and dysfunction

 
  • Loss of mass and dysfunction

  • Inflammatory response

 
  • No mechanical ventilation or immobilisation

 
[112,123,148
Mice Sepsis; Streptococcus pneumoniae
(intranasal) 
Fluid resuscitation with antibiotics 
  • Reduced contractility of the diaphragm

 
  • ICU-like standard care

  • Inflammatory response

  • Muscle weakness of the diaphragm

 
  • Short duration

  • No hindlimb wasting or weakness

  • No mechanical ventilation or immobilisation

 
[125
Pigs Sepsis; Pseudomonas aeruginosa
(i.v.) 
Fluid resuscitation 
  • Muscle inflammatory infiltrate

 
  • ICU-like standard of care

  • Repeat blood sampling

  • Immune system similarity to humans

 
  • No muscle wasting or dysfunction

  • No mechanical ventilation or immobilisation

  • Cost-prohibitive

  • Labour intense

 
[149
Faecal (caecal) slurry 
Mice Sepsis; polymicrobial
(i.p.) 
Limited 
  • Muscle atrophy and dysfunction

  • Inflammatory infiltrate

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Capacity for investigations into long-term dysfunction

 
  • No mechanical ventilation or immobilisation

  • Standardisation can be difficult

 
[130,133,134
Rats Sepsis; polymicrobial
(i.p.) 
Fluid resuscitation 
  • Biogenetic abnormalities

 
  • ICU-like standard care

  • Mitochondrial dysfunction

 
  • No mechanical ventilation or immobilisation

  • Standardisation can be difficult

 
[131
Pigs Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, antibiotics 
  • Electrophysiological abnormalities

 
  • ICU-like standard care

  • Mechanical ventilation and immobilisation

 
  • Cost-prohibitive

  • Labour intense

 
[132
Sterile inflammation and endotoxemia 
C2C12 cells LPS; Systemic inflammation N/A 
  • Myotube atrophy

  • Reduced fusion index

  • Inflammation

  • Increased catabolism

  • Increased autophagy

 
  • Examination of muscle in isolation

  • Atrophy

  • Increased catabolism

 
  • Absence of systemic interactions

 
[150–152
Mice LPS; Systemic inflammation
(i.p., i.v., intratracheal
Limited 
  • Muscle atrophy and dysfunction

  • Increased inflammation

  • Increased catabolism

  • Reduced protein synthesis

  • Increased autophagy

  • Anabolic resistance

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Anabolic resistance

 
  • Acute inflammatory response

  • Usually short in duration

  • No mechanical ventilation or immobilisation

 
[150,151,153–156
Rats LPS; Systemic inflammation
(i.p., i.v.) 
Fluid resuscitation 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced oxidative capacity

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • Acute inflammatory response

  • Usually short in duration

  • No mechanical ventilation or immobilisation

 
[157–161
Guinea pig LPS; Systemic inflammation
(Intranasal) 
Limited 
  • Muscle atrophy

 
  • Loss of muscle mass

 
  • No mechanical ventilation/ immobilisation

 
[162
Pigs LPS; Systemic inflammation
(i.p, i.v.) 
Fluid resuscitation, haemodynamic maintenance 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care,

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Immune system similarity to humans

  • Mechanical ventilation and immobilisation

 
  • Cost-prohibitive

  • Labour intense

 
[163–166
Rats Zymosan; Peritonitis
(i.p.) 
Limited 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis

  • Increased autophagy

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Recovery model

 
  • No mechanical ventilation or immobilisation

 
[167,168
Corticosteroids with denervation 
Rats Sciatic nerve denervation, corticosteroids N/A 
  • Muscle atrophy and dysfunction

  • Disorganised sarcomeres

  • Electrophysiological abnormalities

 
  • Loss of mass and dysfunction

  • Altered protein balance

 
  • Nerve primarily intact in patients (trophic signalling from endplate)

  • No critical illness

  • No mechanical ventilation or immobilisation

 
[169–171
Intensive Care Unit (ICU
Rats Immobilisation, mechanical ventilation, neuromuscular blockers Limited 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care

  • Loss of mass and dysfunction

  • Altered protein balance

  • Mechanical ventilation and immobilisation

  • Long term model

 
  • No critical illness

  • Labour intense

 
[22,172
Burn injury 
Mice Inflammation Fluid resuscitation and analgesic 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased catabolism

  • Decreased protein signalling pathways

 
  • ICU-like standard care

  • Muscle atrophy and dysfunction

  • Inflammation

  • Altered protein balance

 
  • No mechanical ventilation or immobilisation

 
[173,174
Rats Inflammation Fluid resuscitation and analgesic 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care

  • Muscle atrophy and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • No mechanical ventilation or immobilisation

 
[175–177
Immobilisation (limb casting and hindlimb suspension
Mice Immobilisation N/A 
  • Muscle atrophy

  • Increased catabolism

  • Reduced protein synthesis

 
  • Muscle atrophy

  • Altered protein balance

  • Anabolic resistance

  • Immobilisation

 
  • No critical illness

  • No mechanical ventilation

 
[178–180
Rats Immobilisation N/A 
  • Muscle atrophy

  • Increased catabolism

  • Reduced protein synthesis

 
  • Muscle atrophy

  • Altered protein balance

  • Anabolic resistance

  • Immobilisation

 
  • No critical illness

  • No mechanical ventilation

 
[181,182
Patient serum 
C2C12 cells Critical illness N/A 
  • Atrophy with loss of myosin

  • Increased catabolism

 
  • Isolation of muscle only effect

  • Atrophy and increased catabolism

 
  • Lack of systemic interaction

 
[183
Human primary cells Critical illness N/A 
  • Aberrant autophagy

 
  • Differential autophagy response

 
  • Lack of systemic interaction

 
[184
Animal/ Cell typePathology induced
(administration route)
Welfare supportSkeletal muscle phenotypeClinical phenotype and translational weaknessesRef.
StrengthsWeaknesses
Caecal ligation and puncture (CLP
Mice Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, antibiotics and analgesic optional 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased protein catabolism

  • Reduced protein synthesis

  • Disorganised sarcomeres

  • Anabolic resistance

 
  • Sepsis progression similar to humans

  • ICU-like standard care

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[98–101,145,146
Rats Sepsis; poly-microbial
(surgical) 
Fluid resuscitation and analgesic optional 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased protein catabolism

  • Reduced protein synthesis

  • Disorganised sarcomeres

  • Hypoexcitability

 
  • Sepsis progression similar to humans

  • ICU-like standard care

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Nerve pathology

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[104,105,107
Pigs Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, haemodynamic maintenance, analgesic and anti-inflammatories 
  • Muscle atrophy

  • Increased protein catabolism

  • Reduced protein synthesis

 
  • ICU-like standard of care

  • Loss of mass

  • Altered protein balance

  • Repeat blood sampling

  • Immune system similarity to humans

 
  • No mechanical ventilation or immobilisation

  • Cost prohibitive

  • Labour intense

 
[106
Inoculation with live bacteria 
Mice Sepsis; Escherichia coli
(i.p.) 
Limited 
  • Muscle atrophy

 
  • Loss of mass

 
  • Usually short duration

  • No mechanical ventilation or immobilisation

 
[147
Rats Sepsis; Escherichia coli
(i.p., i.v.) 
Limited 
  • Muscle atrophy and dysfunction

 
  • Loss of mass and dysfunction

  • Inflammatory response

 
  • No mechanical ventilation or immobilisation

 
[112,123,148
Mice Sepsis; Streptococcus pneumoniae
(intranasal) 
Fluid resuscitation with antibiotics 
  • Reduced contractility of the diaphragm

 
  • ICU-like standard care

  • Inflammatory response

  • Muscle weakness of the diaphragm

 
  • Short duration

  • No hindlimb wasting or weakness

  • No mechanical ventilation or immobilisation

 
[125
Pigs Sepsis; Pseudomonas aeruginosa
(i.v.) 
Fluid resuscitation 
  • Muscle inflammatory infiltrate

 
  • ICU-like standard of care

  • Repeat blood sampling

  • Immune system similarity to humans

 
  • No muscle wasting or dysfunction

  • No mechanical ventilation or immobilisation

  • Cost-prohibitive

  • Labour intense

 
[149
Faecal (caecal) slurry 
Mice Sepsis; polymicrobial
(i.p.) 
Limited 
  • Muscle atrophy and dysfunction

  • Inflammatory infiltrate

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Capacity for investigations into long-term dysfunction

 
  • No mechanical ventilation or immobilisation

  • Standardisation can be difficult

 
[130,133,134
Rats Sepsis; polymicrobial
(i.p.) 
Fluid resuscitation 
  • Biogenetic abnormalities

 
  • ICU-like standard care

  • Mitochondrial dysfunction

 
  • No mechanical ventilation or immobilisation

  • Standardisation can be difficult

 
[131
Pigs Sepsis; polymicrobial
(surgical) 
Fluid resuscitation, antibiotics 
  • Electrophysiological abnormalities

 
  • ICU-like standard care

  • Mechanical ventilation and immobilisation

 
  • Cost-prohibitive

  • Labour intense

 
[132
Sterile inflammation and endotoxemia 
C2C12 cells LPS; Systemic inflammation N/A 
  • Myotube atrophy

  • Reduced fusion index

  • Inflammation

  • Increased catabolism

  • Increased autophagy

 
  • Examination of muscle in isolation

  • Atrophy

  • Increased catabolism

 
  • Absence of systemic interactions

 
[150–152
Mice LPS; Systemic inflammation
(i.p., i.v., intratracheal
Limited 
  • Muscle atrophy and dysfunction

  • Increased inflammation

  • Increased catabolism

  • Reduced protein synthesis

  • Increased autophagy

  • Anabolic resistance

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Anabolic resistance

 
  • Acute inflammatory response

  • Usually short in duration

  • No mechanical ventilation or immobilisation

 
[150,151,153–156
Rats LPS; Systemic inflammation
(i.p., i.v.) 
Fluid resuscitation 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced oxidative capacity

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • Acute inflammatory response

  • Usually short in duration

  • No mechanical ventilation or immobilisation

 
[157–161
Guinea pig LPS; Systemic inflammation
(Intranasal) 
Limited 
  • Muscle atrophy

 
  • Loss of muscle mass

 
  • No mechanical ventilation/ immobilisation

 
[162
Pigs LPS; Systemic inflammation
(i.p, i.v.) 
Fluid resuscitation, haemodynamic maintenance 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care,

  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Immune system similarity to humans

  • Mechanical ventilation and immobilisation

 
  • Cost-prohibitive

  • Labour intense

 
[163–166
Rats Zymosan; Peritonitis
(i.p.) 
Limited 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis

  • Increased autophagy

 
  • Loss of mass and dysfunction

  • Inflammatory response

  • Altered protein balance

  • Recovery model

 
  • No mechanical ventilation or immobilisation

 
[167,168
Corticosteroids with denervation 
Rats Sciatic nerve denervation, corticosteroids N/A 
  • Muscle atrophy and dysfunction

  • Disorganised sarcomeres

  • Electrophysiological abnormalities

 
  • Loss of mass and dysfunction

  • Altered protein balance

 
  • Nerve primarily intact in patients (trophic signalling from endplate)

  • No critical illness

  • No mechanical ventilation or immobilisation

 
[169–171
Intensive Care Unit (ICU
Rats Immobilisation, mechanical ventilation, neuromuscular blockers Limited 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care

  • Loss of mass and dysfunction

  • Altered protein balance

  • Mechanical ventilation and immobilisation

  • Long term model

 
  • No critical illness

  • Labour intense

 
[22,172
Burn injury 
Mice Inflammation Fluid resuscitation and analgesic 
  • Muscle atrophy and dysfunction

  • Mitochondrial dysfunction

  • Increased catabolism

  • Decreased protein signalling pathways

 
  • ICU-like standard care

  • Muscle atrophy and dysfunction

  • Inflammation

  • Altered protein balance

 
  • No mechanical ventilation or immobilisation

 
[173,174
Rats Inflammation Fluid resuscitation and analgesic 
  • Muscle atrophy and dysfunction

  • Increased catabolism

  • Reduced protein synthesis pathways

 
  • ICU-like standard care

  • Muscle atrophy and dysfunction

  • Inflammatory response

  • Altered protein balance

 
  • No mechanical ventilation or immobilisation

 
[175–177
Immobilisation (limb casting and hindlimb suspension
Mice Immobilisation N/A 
  • Muscle atrophy

  • Increased catabolism

  • Reduced protein synthesis

 
  • Muscle atrophy

  • Altered protein balance

  • Anabolic resistance

  • Immobilisation

 
  • No critical illness

  • No mechanical ventilation

 
[178–180
Rats Immobilisation N/A 
  • Muscle atrophy

  • Increased catabolism

  • Reduced protein synthesis

 
  • Muscle atrophy

  • Altered protein balance

  • Anabolic resistance

  • Immobilisation

 
  • No critical illness

  • No mechanical ventilation

 
[181,182
Patient serum 
C2C12 cells Critical illness N/A 
  • Atrophy with loss of myosin

  • Increased catabolism

 
  • Isolation of muscle only effect

  • Atrophy and increased catabolism

 
  • Lack of systemic interaction

 
[183
Human primary cells Critical illness N/A 
  • Aberrant autophagy

 
  • Differential autophagy response

 
  • Lack of systemic interaction

 
[184

a) Lipopolysaccharide

LPS, a form of endotoxin, is found in the cell wall of all gram-negative bacteria [185] and released from the cell after death [186]. These endotoxins can be isolated and purified [187] for use in eliciting a sterile inflammatory response in model organisms. LPS binds to LPS-binding protein (LBP), which activates the CD14 receptor on the cell membrane of immune cells [188]. The interaction of CD14 with MD2 facilitates signalling through TLR4 to elicit a downstream inflammatory response [189]. LPS is not a model of sepsis per se, since it does not produce a prolonged, sustained increase in circulating cytokines [126]. To circumvent this shortcoming, some studies provide a continual infusion of LPS to host organisms, although this scenario is not representative of how septic patients are normally exposed to a pathogen [126]. LPS is used to model muscle inflammation and wasting associated with a systemic inflammatory insult.

LPS exposure significantly reduces muscle mass in mice [150,153,190], rats [157–159] and guinea pigs [162], with the initiation of wasting occurring as early as 24 hours later with higher doses (5 mg/kg) [191]. Loss of muscle mass and decreased forelimb grip strength have been reported in mice ten days after LPS exposure [150]. Variation in the wasting phenotype is caused by variability in the dose, with concentrations ranging from 1 to 50 mg/kg. LPS administration (i.p.) also results in a loss of muscle mass in the rat diaphragm 48 hours after exposure, which preceded the reduction in specific force of isolated diaphragm muscle strips ex vivo [157]. Studies using LPS in pigs have incorporated ICU-like standard care to maintain the haemodynamic system and allow for examination of additional risk factors for muscle wasting, including mechanical ventilation and immobilisation [163–165]. Skeletal muscle dysfunction was observed in pigs five days after LPS exposure, with single fibres isolated from the biceps femoris muscle having reduced specific force across all fibre types [166]. Large animal models are commonly used to examine how inflammation affects nutritional feeding strategies and how anabolic resistance may limit the efficacy of nutritional interventions [151,192,193].

The use of endotoxin models as sepsis surrogates is common, but these do not recapitulate the inflammatory state of true sepsis. Rather, they serve to investigate the initiation of a muscle wasting phenotype associated with acute systemic inflammation. LPS remains a useful and reproducible model for understanding mechanisms associated with anabolic resistance in response to inflammation and the associated muscle wasting.

b) Zymosan

The zymosan model of peritonitis was originally developed to demonstrate that a sterile inflammatory response could mimic signs of sepsis and cause multiple organ failure [194]. Extracted from the cell wall of the fungus Saccharomyces cerevisiae, zymosan activates a systemic inflammatory response through various mechanisms, including TLR-2 [195,196] and the host’s complement system [196,197]. Unlike other inflammatory models, the suspension of zymosan in liquid paraffin allows for a sustained inflammatory response, which more closely resembles the phenotype of multi-organ dysfunction in critically ill patients [167,168,196].

The zymosan model has been used to study mechanisms of skeletal muscle wasting and weakness with critical illness, particularly with respect to the recovery of muscle mass and function once the illness has resolved [167,168,198–206]. Recovery of muscle mass and function was evident at 12–14 days post zymosan administration in rats. The peak reduction in hindlimb force in situ occurred on day 2 [167] and at day 6 [199,204], with the loss of functional capacity consistent with the muscle atrophy. Functional recovery, based on treadmill running duration, occurred 14 days after zymosan administration [167].

Unlike terminal models of critical illness, or long-term models of dysfunction such as the CS, the zymosan model facilitates investigation of mechanisms responsible for the recovery of muscle mass and function. The translational significance of the zymosan model would benefit from further studies investigating how risk factors/variables such as age and sex affect skeletal muscle structure, function and metabolism during critical illness, particularly whether aged mice can similarly recover from such an insult.

Hypercatabolic models

a) Burn injury

One of the hallmarks of many of the models presented herein is acute hypothermia at the onset of sepsis, with a concomitant reduction in oxygen consumption and metabolic rate [167,207–209]. However, in clinical situations, such as burn injury, there is a hypercatabolic response which also leads to significant muscle wasting and weakness. Burn injuries are a common presentation to the ICU, and patients often experience a loss of muscle mass and function [210]. While burn injury is characterised by a systemic inflammatory response like that experienced by most critically ill patients, the type of burn injury, i.e., thermal, electrical, or chemical, can cause differential effects on the skeletal muscles of patients [210]. Burn models in mice [173,174], rats [175–177] and rabbits [211] have incorporated fluid resuscitation and analgesics in their interrogation of skeletal muscle wasting. Muscle atrophy and dysfunction due to increased catabolism and decreased protein synthesis have been reported in these model systems. Burn injury provides an alternative route of critical illness induction, but further investigations of the differential muscle responses based on the type of burn injury could provide mechanistic insight for optimising therapeutic development.

Combination and risk factor models

Some models of critical illness are not initiated directly by inflammation and are used to investigate other risk factors associated with the development of muscle wasting and weakness in the ICU (Figure 1, Table 1). Patients admitted to the ICU may be affected by other compounding factors that exacerbate muscle wasting and weakness. Incorporating these risk factors into pre-clinical models can provide insight into the mechanisms underlying muscle dysfunction and are important in the development of effective therapeutics.

a) Corticosteroids with denervation

Patients in the ICU are often sedated and immobilised and so to examine the effect of this ‘mechanical silencing’ and the local and systemic environments that promote muscle wasting, sciatic nerve denervation in rats has been combined with corticosteroid treatment for a two-pronged insult that results in muscle wasting and weakness like in critically ill patients [169]. In this model, hallmarks of wasting and weakness include muscle atrophy [169,170] after seven days and a preferential loss of myosin, findings similar to those observed in patients with critical illness myopathy, a subset of ICU-AW [8]. In that study, muscle dysfunction was based on the reduction in specific force of rat plantar flexor muscles in situ [169]. Electrophysiological abnormalities have also been reported in this model, with muscle fibres exhibiting a hyperpolarising shift in the voltage dependence of fast inactivation of Na+ channels responsible for their inexcitability [171].

Although one of the few models to mimic the reduction of the myosin/actin ratio like that in critically ill patients, this model does not involve a systemic inflammatory response like that typically presented by patients in the ICU. The ‘mechanical silencing’ in this model also differs from that in patients where the nerve is primarily intact and trophic signalling from the motor endplate is not compromised. These differences highlight potential limitations in translating findings from the animal model to the clinic.

b) Mechanical ventilation and neuromuscular blockade

Interventions to treat critically ill patients in the ICU can also contribute to muscle wasting and weakness. These include mechanical ventilation, immobilisation and use of neuromuscular blocking agents [8]. Insights into the influence of these risk factors on skeletal muscle have come from studies utilising a model where rats are sedated, mechanically ventilated, and administered neuromuscular blocking agents [22,172]. In this environment, rats exhibit atrophy, dysfunction and altered protein metabolism in the hindlimb muscles [172] and diaphragm [22]. Hindlimb muscle dysfunction is evident at the single fibre level after 5 days, with reduced specific force of soleus muscle fibres [212], attributed to impaired Ca2+ signalling and reduced sarcoplasmic reticulum (SR) Ca2+ release after eight to ten days [213]. The hindlimb muscle wasting associated with a reduced myosin/actin ratio was similar to that in patients with critical illness myopathy [172]. However, the myosin/actin ratio was unchanged in the diaphragm muscles of these rats, indicating a possible different mechanism of wasting compared with that in hindlimb muscles [22]. Muscle dysfunction was evident even within six hours after onset of mechanical ventilation, with the diaphragm pathology progressively worsening, and functional impairments preceding muscle fibre atrophy.

While this model provides important insights into mechanical ventilation dysfunction, ICU-AW is induced in the absence of systemic inflammatory mediators and differs from the critical illness experienced by patients. Furthermore, continual heavy sedation and use of neuromuscular blocking agents throughout mechanical ventilation only occurs in a limited number of ICU patients, with many requiring only light sedation without neuromuscular blockade, limiting some aspects of its clinical relevance.

c) Disuse

Disuse is one of the main risk factors for the development of acquired myopathies in the ICU. In rodents, models such as hindlimb suspension (HLS) and limb casting are often used as surrogates of the ICU environment (Table 1). These include skeletal muscle atrophy [178,181,214] after 7 [178] and 14 [214] days of disuse, and reduced puromycin incorporation after 3 days of disuse [179], indicating impaired protein synthesis. However, disuse models in isolation do not replicate the systemic inflammation in critically ill patients and do not account for long-term dysfunction, even after muscle loading and normal nutrition have been restored.

HLS protocols have been combined with critical illness models, such as CLP-induced sepsis [59,145], to try and provide greater insight into the mechanisms underlying ICU-AW. The combination of CLP followed by seven days of HLS, four days after sepsis induction, induces more severe muscle atrophy [145], and remodelling of the entire muscle proteome [215] compared with sepsis alone. HLS was associated with greater inflammatory response [59] and exacerbated dysfunction of the soleus muscle compared with sham and CLP-only groups, with impairments in ex vivo measures of maximum absolute force and specific force [59,145]. However, HLS models are more closely representative of microgravity environments compared with the disuse observed in the ICU [216].

Limb casting protocols, which involve complete immobilisation of the affected limb, more closely resemble the disuse observed in the ICU. Limb casting in combination with CLP-induced sepsis exacerbated the muscle atrophic response and reductions in hindlimb grip strength in mice compared with mice with sepsis alone [217]. However, the effects of limb casting models are only isolated to the limbs. In the ICU, patients are often mechanically ventilated and experience complete whole-body mechanical silencing of the skeletal muscles. Limb casting models facilitate investigation of the effect of critical illness in an ICU-like environment on diaphragm pathology not induced by mechanical ventilation. A combination of models may provide greater insight into the muscle impairments experienced by patients in the ICU and is important for the development of effective interventions.

In vitro models of muscle wasting and weakness associated with critical illness

Animal models are not the only useful system for interrogating mechanisms underlying muscle wasting and weakness associated with critical illness. Muscle cell culture systems facilitate investigation of how circulating factors affect skeletal muscle cells, helping to identify causes of muscle atrophy and weakness. For example, endotoxins such as LPS provide an effective and reproducible way of inducing inflammatory responses in vitro. In mono-culture systems of a single cell type, such as the immortalised murine muscle C2C12 cell line, administration of LPS at various stages of the cell cycle induces an inflammatory response from the muscle cells. Compared with in vivo models where LPS elicits an immune response that activates a systemic inflammatory response which can affect the muscle, the culture experiments permit evaluation of the muscle cell response directly and in isolation.

LPS exposure reduces myotube diameter of C2C12 muscle cells after 24 [151] and 48 hours [150,153]. In vitro experiments permit analysis of these inflammatory agents at different stages of myogenesis, including proliferation and differentiation. C2C12 myoblasts exposed to LPS had an impaired differentiation capacity [218], with implications for explaining compromised muscle regeneration after a bout of sepsis [219]. Mature C2C12 myotubes treated with recombinant IL-6 exhibited a wasting phenotype like that with LPS, as early as 24 hours [100]. However, the systemic inflammation associated with critical illness does not simply involve elevation of a single cytokine. Therefore, supplementing cells with serum isolated from critically ill patients allows for a more patient-relevant assessment of how circulating factors can affect skeletal muscles directly [183]. Similarly, co-culture systems investigating LPS activation of macrophages cultured with C2C12 muscle cells [154] may better replicate a more physiological environment. Rather than utilising immortalised cell lines, a system utilising human primary myoblasts isolated from the vastus lateralis muscles of otherwise healthy patients revealed aberrant autophagic responses when incubated with the serum from critically ill patients [184]. Application of serum from critically ill patients on isolated cell systems in vitro may facilitate investigation of the circulating factors influencing human skeletal muscle, thus increasing the clinical translation and relevance of these studies.

While cell culture systems can be used to screen anti-inflammatory and anti-catabolic effects of different interventions, they are limited by not adequately modelling the organ-system interactions within a whole body, integrated physiological system. Three-dimensional (3-D) organoid culture systems derived from primary myoblasts are more like skeletal muscle than typical two-dimensional cell culture systems. Three-dimensional muscle organoid culture systems, or ‘micro muscles’, can be electrically stimulated to contract and forces measured [220]. Such 3-D systems can be utilised as a high-throughput method for drug discovery relevant to critical illness, with applications potentially using conditioned media from macrophages stimulated with LPS or incubated with serum derived from patients. Despite the usefulness of in vitro systems in facilitating investigation of muscle-specific effects, these systems are generally representative of immature skeletal muscle with limited expression of more mature myosin isoforms. Other factors associated with the development of ICU-AW, such as disuse, are also difficult to assess in vitro.

Summary

Skeletal muscle wasting and weakness associated with critical illness impairs quality of life and is associated with prolonged dysfunction post-discharge from the ICU. Despite this burden of disease on patients, there are currently no effective therapies. Treatment options are limited to the modification of disuse, recognising that early mobilisation may not be possible for all patients due to the severity of their illness or because of staffing limitations in the clinic. Hence, there is an urgent need to develop effective pharmacotherapies and nutritional interventions that can be administered to all patients alongside the standard of care. Understanding the mechanisms responsible for critical illness, muscle wasting and weakness will provide greater insight into the development of these treatments. Conducting mechanistic studies in the clinic is challenging because of interpatient variability and an inability to obtain sufficient muscle tissue from biopsies to perform comprehensive analyses. The most common muscles analysed in the context of critical illness in pre-clinical animal studies include the tibialis anterior, soleus and diaphragm muscles, but comprehensive comparisons between different muscle groups are not common. In addition, the quadriceps, which is the most biopsied muscle in patients [11,22,23], is rarely investigated in pre-clinical studies using animal models. Assessments of different muscle groups are important because fibre composition differs between these muscles, which affects their functional characteristics. The tibialis anterior and quadriceps muscles have a largely force-producing function, whereas the soleus muscle has more of a postural function and its fibre composition makes it resistant to fatigue. The diaphragm is the muscle of respiration, and critically ill patients often experience diaphragm dysfunction requiring mechanical ventilation, which itself can lead to intrinsic muscle weakness. Examining different muscle groups is important for answering key questions regarding the mechanisms underlying ICU-AW, including (1) Are all muscle groups equally affected in critical illness settings or does muscle fibre composition confer protection for some muscle groups? (2) What is the role of the diaphragm in the overall physical dysfunction (in some patients) after discharge from the ICU?

Are current models sufficient? Models of critical illness can provide insight into the mechanisms of wasting and weakness in ICU patients. Cell culture systems provide a platform for examining how inflammatory stimuli affect isolated muscle cells and facilitate evaluative screening of potential therapies to protect muscles from atrophy. However, cell culture systems are typically representative of immature skeletal muscle (expressing less mature myosin isoforms) and lacking the physiological integration of animal models. Animal models can enhance understanding of critical illness and ICU-AW as they allow for investigation of inter-organ signalling and integrated systems physiology. This is essential for robust interrogation of how inflammatory signalling disrupts the molecular pathways regulating skeletal muscle homeostasis. Some of these models have employed ICU-like standard care, including fluid resuscitation, antibiotics and analgesics, and in some cases have utilised mechanical ventilation and immobilisation/disuse.

Despite the development of animal models of ICU-AW across different species, most models do not completely mimic critical illness/ICU settings in human patients, and to date, no effective treatments for muscle wasting and weakness have advanced to the clinic. Most animal models are not representative of typical ICU patient populations and might account for limited admission categories, such as mechanical ventilation or sepsis, and often study only young, healthy animals rather than older animals that would more closely mimic the age of older patients in the ICU. Few animal models exhibit the muscle weakness experienced by many survivors of critical illness during their (often prolonged) recovery after hospital discharge.

Recommended pre-clinical workflow

There is currently no standard animal model that best replicates the hallmarks of ICU-AW. Ideally, an animal model would include the following characteristics: (1) be representative of the age of a typical ICU population. For rodent models, this would require using older rats or mice between 18–24 months of age, recognising that the availability of older rodents is usually limited and often cost-prohibitive; (2) mimic a critical illness phenotype that leads to multi-organ dysfunction in the absence of disuse; (3) include a component of disuse given that inactivity and lack of mechanical loading contribute to muscle atrophy and weakness; (4) include sedation and mechanical ventilation where feasible, recognising that such experiments are technically very challenging and labour intensive; (6) have a time course that more closely represents the development of ICU-AW (i.e. for seven days or longer); and (7) include the capacity to recover from critical illness to facilitate investigations into long-term physical dysfunction after ICU discharge. Large animal models, such as pigs, have a similar immune system to that in humans and facilitate repeated blood sampling, which more closely mimics clinical evaluations in ICU settings. However, they are often prohibitively expensive and not used widely. Smaller animal models, such as rats and mice, allow for higher throughput analyses and mechanistic studies through genetic manipulation. Despite their obvious limitations, cell and animal models can provide important insights into the mechanisms underlying critical illness and ICU-AW and are critical for the development and evaluation of therapies for potential clinical translation.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this review.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ADL

activities of daily living

ARDS

acute respiratory distress syndrome

CASP

colon ascendens stent peritonitis

CLP

caecal ligation and puncture

CS

caecal slurry

CSA

cross-sectional area

3-D

three-dimensional

EDL

extensor digitorum longus

EMG

electromyography

EMS

electrical muscle stimulation

ICU

intensive care unit

ICU-AW

ICU-acquired weakness

LBP

lipopolysaccharide binding protein

LPS

lipopolysaccharide

NMBs

neuromuscular blockers

PAMP

pathogen associated molecular pattern

PICU

paediatric intensive care unit

SOFA

Sequential Organ Failure Assessment

TA

tibialis anterior

TLR

Toll-like receptor

i.p.

intraperitoneal

i.v.

intravenous

1
Vanhorebeek
,
I.
,
Latronico
,
N.
and
Van den Berghe
,
G
. (
2020
)
ICU-acquired weakness
.
Intensive Care Med.
46
,
637
653
https://doi.org/10.1007/s00134-020-05944-4
2
Dos Santos
,
C.
,
Hussain
,
S.N.
,
Mathur
,
S.
,
Picard
,
M.
,
Herridge
,
M.
,
Correa
,
J.
et al
. (
2016
)
Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A pilot study
.
Am. J. Respir. Crit. Care Med.
194
,
821
830
https://doi.org/10.1164/rccm.201512-2344OC
3
Herridge
,
M.S.
,
Tansey
,
C.M.
,
Matté
,
A.
,
Tomlinson
,
G.
,
Diaz-Granados
,
N.
,
Cooper
,
A.
et al
. (
2011
)
Functional disability 5 years after acute respiratory distress syndrome
.
N. Engl. J. Med.
364
,
1293
1304
https://doi.org/10.1056/NEJMoa1011802
4
Iwashyna
,
T.J.
,
Ely
,
E.W.
,
Smith
,
D.M.
and
Langa
,
K.M
. (
2010
)
Long-term cognitive impairment and functional disability among survivors of severe sepsis
.
JAMA
304
,
1787
1794
https://doi.org/10.1001/jama.2010.1553
5
Herridge
,
M.S.
and
Azoulay
,
É
. (
2023
)
Outcomes after critical illness
.
N. Engl. J. Med.
388
,
913
924
https://doi.org/10.1056/NEJMra2104669
6
Osler
,
W
. (
1892
)
The Principles and Practice of Medicine
,
D Appleton
,
New York
7
Bolton
,
C.F
. (
2008
)
The discovery of critical illness polyneuropathy
.
Eur. J. Anaesthesiol. Suppl.
42
,
66
67
https://doi.org/10.1017/S0265021508003530
8
Friedrich
,
O.
,
Reid
,
M.B.
,
Van den Berghe
,
G.
,
Vanhorebeek
,
I.
,
Hermans
,
G.
,
Rich
,
M.M.
et al
. (
2015
)
The sick and the weak: Neuropathies/Myopathies in the critically ill
.
Physiol. Rev.
95
,
1025
1109
https://doi.org/10.1152/physrev.00028.2014
9
Stevens
,
R.D.
,
Marshall
,
S.A.
,
Cornblath
,
D.R.
,
Hoke
,
A.
,
Needham
,
D.M.
, de Jonghe, B. et al
. (
2009
)
A framework for diagnosing and classifying intensive care unit-acquired weakness
.
Crit. Care Med
37 (10 Suppl)
,
S299
308
https://doi.org/10.1097/CCM.0b013e3181b6ef67
10
Fetterplace
,
K.
,
Gill
,
B.M.T.
,
Chapple
,
L.S.
,
Presneill
,
J.J.
,
MacIsaac
,
C.
and
Deane
,
A.M
. (
2020
)
Systematic review with meta-analysis of patient-centered outcomes, comparing international guideline-recommended enteral protein delivery with usual care
.
JPEN J. Parenter. Enteral Nutr.
44
,
610
620
https://doi.org/10.1002/jpen.1725
11
Puthucheary
,
Z.A.
,
Rawal
,
J.
,
McPhail
,
M.
,
Connolly
,
B.
,
Ratnayake
,
G.
,
Chan
,
P.
et al
. (
2013
)
Acute skeletal muscle wasting in critical illness
.
JAMA
310
,
1591
1600
https://doi.org/10.1001/jama.2013.278481
12
Fazzini
,
B.
,
Märkl
,
T.
,
Costas
,
C.
,
Blobner
,
M.
,
Schaller
,
S.J.
,
Prowle
,
J.
et al
. (
2023
)
The rate and assessment of muscle wasting during critical illness: a systematic review and meta-analysis
.
Crit. Care
27
, 2 https://doi.org/10.1186/s13054-022-04253-0
13
Latronico
,
N.
,
Herridge
,
M.
,
Hopkins
,
R.O.
,
Angus
,
D.
,
Hart
,
N.
,
Hermans
,
G.
et al
. (
2017
)
The ICM research agenda on intensive care unit-acquired weakness
.
Intensive Care Med.
43
,
1270
1281
https://doi.org/10.1007/s00134-017-4757-5
14
Williams
,
T.A.
,
Dobb
,
G.J.
,
Finn
,
J.C.
,
Knuiman
,
M.W.
,
Geelhoed
,
E.
,
Lee
,
K.Y.
et al
. (
2008
)
Determinants of long-term survival after intensive care
.
Crit. Care Med.
36
,
1523
1530
https://doi.org/10.1097/CCM.0b013e318170a405
15
Cuthbertson
,
B.H.
,
Roughton
,
S.
,
Jenkinson
,
D.
,
Maclennan
,
G.
and
Vale
,
L
. (
2010
)
Quality of life in the five years after intensive care: a cohort study
.
Crit. Care
14
, R6 https://doi.org/10.1186/cc8848
16
Dres
,
M.
,
Dubé
,
B.P.
,
Mayaux
,
J.
,
Delemazure
,
J.
,
Reuter
,
D.
,
Brochard
,
L.
et al
. (
2017
)
Coexistence and impact of limb muscle and diaphragm weakness at time of liberation from mechanical ventilation in medical intensive care unit patients
.
Am. J. Respir. Crit. Care Med.
195
,
57
66
https://doi.org/10.1164/rccm.201602-0367OC
17
Sharshar
,
T.
,
Bastuji-Garin
,
S.
,
Stevens
,
R.D.
,
Durand
,
M.C.
,
Malissin
,
I.
,
Rodriguez
,
P.
et al
. (
2009
)
Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality*
.
Crit. Care Med.
37
,
3047
3053
https://doi.org/10.1097/CCM.0b013e3181b027e9
18
Medical Research Council
. (
1943
)
Aids to the Examination of the Peripheral Nervous System
, 2, revised ed
ed
,
H.M.S.O
,
London
19
Ashir
,
A.
,
Jerban
,
S.
,
Barrère
,
V.
,
Wu
,
Y.
,
Shah
,
S.B.
,
Andre
,
M.P
. et al
. (
2023
)
Skeletal muscle assessment using quantitative ultrasound: a narrative review
.
Sensors (Basel).
23
, 4763 https://doi.org/10.3390/s23104763
20
Tuinman
,
P.R.
,
Jonkman
,
A.H.
,
Dres
,
M.
,
Shi
,
Z.H.
,
Goligher
,
E.C.
,
Goffi
,
A.
et al
. (
2020
)
Respiratory muscle ultrasonography: methodology, basic and advanced principles and clinical applications in Icu and Ed patients-a narrative review
.
Intensive Care Med.
46
,
594
605
https://doi.org/10.1007/s00134-019-05892-8
21
Bragança
,
R.D.
,
Ravetti
,
C.G.
,
Barreto
,
L.
,
Ataíde
,
T.
,
Carneiro
,
R.M.
,
Teixeira
,
A.L
. et al
. (
2019
)
Use of handgrip dynamometry for diagnosis and prognosis assessment of intensive care unit acquired weakness: a prospective study
.
Heart Lung
48
,
532
537
https://doi.org/10.1016/j.hrtlng.2019.07.001
22
Corpeno
,
R.
,
Dworkin
,
B.
,
Cacciani
,
N.
,
Salah
,
H.
,
Bergman
,
H.M.
,
Ravara
,
B.
et al
. (
2014
)
Time course analysis of mechanical ventilation-induced diaphragm contractile muscle dysfunction in the rat
.
J. Physiol.
592
,
3859
3880
https://doi.org/10.1113/jphysiol.2014.277962
23
Tjäder
,
I.
,
Klaude
,
M.
,
Hssain
,
A.A.
,
Guillet
,
C.
,
Nennesmo
,
I.
,
Wernerman
,
J.
et al
. (
2022
)
Variability in skeletal muscle protein synthesis rates in critically ill patients
.
Nutrients
14
, 3733 https://doi.org/10.3390/nu14183733
24
van den Berg
,
M.
,
Shi
,
Z.
,
Claassen
,
W.J.
,
Hooijman
,
P.
,
Lewis
,
C.T.A.
,
Andersen
,
J.L
. et al
. (
2024
)
Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically ventilated patients
.
Sci. Transl. Med.
16
, eadg3894 https://doi.org/10.1126/scitranslmed.adg3894
25
Nederveen
,
J.P.
,
Ibrahim
,
G.
,
Fortino
,
S.A.
,
Snijders
,
T.
,
Kumbhare
,
D.
and
Parise
,
G
. (
2020
)
Variability in skeletal muscle fibre characteristics during repeated muscle biopsy sampling in human vastus lateralis
.
Appl. Physiol. Nutr. Metab.
45
,
368
375
https://doi.org/10.1139/apnm-2019-0263
26
Weber-Carstens
,
S.
,
Deja
,
M.
,
Koch
,
S.
,
Spranger
,
J.
,
Bubser
,
F.
,
Wernecke
,
K.D.
et al
. (
2010
)
Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study
.
Crit. Care
14
, R119 https://doi.org/10.1186/cc9074
27
Witteveen
,
E.
,
Wieske
,
L.
,
van der Poll
,
T.
,
van der Schaaf
,
M.
,
van Schaik
,
I.N.
,
Schultz
,
M.J
. et al
. (
2017
)
Increased early systemic inflammation in Icu-acquired weakness; a prospective observational cohort study
.
Crit. Care Med
45
,
972
979
https://doi.org/10.1097/CCM.0000000000002408
28
Lambden
,
S.
,
Laterre
,
P.F.
,
Levy
,
M.M.
and
Francois
,
B
. (
2019
)
The SOFA score-development, utility and challenges of accurate assessment in clinical trials
.
Crit. Care
23
, 374 https://doi.org/10.1186/s13054-019-2663-7
29
Smith
,
N.R
. (
1928
)
A Note on the so-called “Disuse” Atrophy of Muscle
.
J. Anat.
62
,
238
240
30
Nunes
,
E.A.
,
Stokes
,
T.
,
McKendry
,
J.
,
Currier
,
B.S.
and
Phillips
,
S.M
. (
2022
)
Disuse-induced skeletal muscle atrophy in disease and nondisease states in humans: mechanisms, prevention, and recovery strategies
.
Am. J. Physiol., Cell Physiol.
322
,
C1068
C1084
https://doi.org/10.1152/ajpcell.00425.2021
31
Phillips
,
S.M.
,
Glover
,
E.I.
and
Rennie
,
M.J
. (
2009
)
Alterations of protein turnover underlying disuse atrophy in human skeletal muscle
.
J. Appl. Physiol.
107
,
645
654
https://doi.org/10.1152/japplphysiol.00452.2009
32
Schweickert
,
W.D.
,
Pohlman
,
M.C.
,
Pohlman
,
A.S.
,
Nigos
,
C.
,
Pawlik
,
A.J.
,
Esbrook
,
C.L.
et al
. (
2009
)
Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial
.
Lancet
373
,
1874
1882
https://doi.org/10.1016/S0140-6736(09)60658-9
33
Eikermann
,
M.
,
Koch
,
G.
,
Gerwig
,
M.
,
Ochterbeck
,
C.
,
Beiderlinden
,
M.
,
Koeppen
,
S.
et al
. (
2006
)
Muscle force and fatigue in patients with sepsis and multiorgan failure
.
Intensive Care Med.
32
,
251
259
https://doi.org/10.1007/s00134-005-0029-x
34
Zhang
,
L.
,
Hu
,
W.
,
Cai
,
Z.
,
Liu
,
J.
,
Wu
,
J.
,
Deng
,
Y.
et al
. (
2019
)
Early mobilization of critically ill patients in the intensive care unit: a systematic review and meta-analysis
.
PLoS ONE
14
, e0223185 https://doi.org/10.1371/journal.pone.0223185
35
Patel
,
B.K.
,
Pohlman
,
A.S.
,
Hall
,
J.B.
and
Kress
,
J.P
. (
2014
)
Impact of early mobilization on glycemic control and Icu-acquired weakness in critically ill patients who are mechanically ventilated
.
Chest
146
,
583
589
https://doi.org/10.1378/chest.13-2046
36
Burtin
,
C.
,
Clerckx
,
B.
,
Robbeets
,
C.
,
Ferdinande
,
P.
,
Langer
,
D.
,
Troosters
,
T.
et al
. (
2009
)
Early exercise in critically ill patients enhances short-term functional recovery*
.
Crit. Care Med.
37
,
2499
2505
https://doi.org/10.1097/CCM.0b013e3181a38937
37
Hodgson
,
C.L.
,
Stiller
,
K.
,
Needham
,
D.M.
,
Tipping
,
C.J.
,
Harrold
,
M.
,
Baldwin
,
C.E.
et al
. (
2014
)
Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults
.
Crit. Care
18
, 658 https://doi.org/10.1186/s13054-014-0658-y
38
Lee
,
C.M.
and
Fan
,
E
. (
2012
)
ICU-acquired weakness: what is preventing its rehabilitation in critically ill patients?
BMC Med.
10
, 115 https://doi.org/10.1186/1741-7015-10-115
39
Murray
,
M.J.
,
DeBlock
,
H.
,
Erstad
,
B.
,
Gray
,
A.
,
Jacobi
,
J.
,
Jordan
,
C.
et al
. (
2016
)
Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient
.
Crit. Care Med.
44
,
2079
2103
https://doi.org/10.1097/CCM.0000000000002027
40
Xu
,
C.
,
Yang
,
F.
,
Wang
,
Q.
and
Gao
,
W
. (
2024
)
Effect of neuromuscular electrical stimulation in critically ill adults with mechanical ventilation: a systematic review and network meta-analysis
.
BMC Pulm. Med.
24
, 56 https://doi.org/10.1186/s12890-024-02854-9
41
Balke
,
M.
,
Teschler
,
M.
,
Schäfer
,
H.
,
Pape
,
P.
,
Mooren
,
F.C.
and
Schmitz
,
B
. (
2022
)
Therapeutic potential of electromyostimulation (EMS) in critically ill patients-a systematic review
.
Front. Physiol.
13
, 865437 https://doi.org/10.3389/fphys.2022.865437
42
Hodgson
,
C.L.
and
Tipping
,
C.J
. (
2017
)
Physiotherapy management of intensive care unit-acquired weakness
.
J. Physiother.
63
,
4
10
https://doi.org/10.1016/j.jphys.2016.10.011
43
Wunsch
,
H.
,
Wagner
,
J.
,
Herlim
,
M.
,
Chong
,
D.H.
,
Kramer
,
A.A.
and
Halpern
,
S.D
. (
2013
)
ICU occupancy and mechanical ventilator use in the United States
.
Crit. Care Med.
41
,
2712
2719
https://doi.org/10.1097/CCM.0b013e318298a139
44
Esteban
,
A.
,
Anzueto
,
A.
,
Frutos
,
F.
,
Alía
,
I.
,
Brochard
,
L.
,
Stewart
,
T.E.
et al
. (
2002
)
Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study
.
JAMA
287
,
345
355
https://doi.org/10.1001/jama.287.3.345
45
Daniel Martin
,
A.
,
Smith
,
B.K.
and
Gabrielli
,
A
. (
2013
)
Mechanical ventilation, diaphragm weakness and weaning: a rehabilitation perspective
.
Respir. Physiol. Neurobiol.
189
,
377
383
https://doi.org/10.1016/j.resp.2013.05.012
46
Cinesi Gómez
,
C.
,
Trigueros Ruiz
,
N.
,
de la Villa Zamora
,
B.
,
Blázquez González
,
L.
,
Piñera Salmerón
,
P.
and
Lázaro Aragüés
,
P
. (
2021
)
Predictors of noninvasive mechanical ventilation weaning failure in the emergency department
.
Emergencias
33
,
9
14
47
Laghi
,
F.
,
Cattapan
,
S.E.
,
Jubran
,
A.
,
Parthasarathy
,
S.
,
Warshawsky
,
P.
,
Choi
,
Y.S.
et al
. (
2003
)
Is weaning failure caused by low-frequency fatigue of the diaphragm?
Am. J. Respir. Crit. Care Med.
167
,
120
127
https://doi.org/10.1164/rccm.200210-1246OC
48
Petrof
,
B.J
. (
2018
)
Diaphragm weakness in the critically ill: basic mechanisms reveal therapeutic opportunities
.
Chest
154
,
1395
1403
https://doi.org/10.1016/j.chest.2018.08.1028
49
Dres
,
M.
,
Goligher
,
E.C.
,
Heunks
,
L.M.A.
and
Brochard
,
LJ
. (
2017
)
Critical illness-associated diaphragm weakness
.
Intensive Care Med.
43
,
1441
1452
https://doi.org/10.1007/s00134-017-4928-4
50
Medrinal
,
C.
,
Prieur
,
G.
,
Frenoy
,
É.
,
Robledo Quesada
,
A.
,
Poncet
,
A.
,
Bonnevie
,
T.
et al
. (
2016
)
Respiratory weakness after mechanical ventilation is associated with one-year mortality - a prospective study
.
Crit. Care
20
, 231 https://doi.org/10.1186/s13054-016-1418-y
51
Borges
,
R.
,
Soriano
,
F.
and
Carvalho
,
C
. (
2018
)
Association between muscle wasting and muscle strength in patients who developed severe sepsis and septic shock
.
Eur. Respir. J.
52 (Suppl 62)
, A4124 https://doi.org/10.1183/13993003.congress-2018.PA4124
52
De Jonghe
,
B.
,
Sharshar
,
T.
,
Lefaucheur
,
J.P.
,
Authier
,
F.J.
,
Durand-Zaleski
,
I.
,
Boussarsar
,
M.
et al
. (
2002
)
Paresis acquired in the intensive care unit: a prospective multicenter study
.
JAMA
288
,
2859
2867
https://doi.org/10.1001/jama.288.22.2859
53
Kelmenson
,
D.A.
,
Held
,
N.
,
Allen
,
R.R.
,
Quan
,
D.
,
Burnham
,
E.L.
,
Clark
,
B.J.
et al
. (
2017
)
Outcomes of ICU patients with a discharge diagnosis of critical illness polyneuromyopathy: a propensity-matched analysis
.
Crit. Care Med.
45
,
2055
2060
https://doi.org/10.1097/CCM.0000000000002763
54
Leijten
,
F.S.S.
,
Weerd
,
J.E.H. d.
,
Poortvliet
,
D.C.J.
and
de Weerd
,
A.W
. (
1995
)
The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation
.
JAMA
274
,
1221
1225
https://doi.org/10.1001/jama.1995.03530150045032
55
Yang
,
T.
,
Li
,
Z.
,
Jiang
,
L.
,
Wang
,
Y.
and
Xi
,
X
. (
2018
)
Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis
.
Acta Neurol. Scand.
138
,
104
114
https://doi.org/10.1111/ane.12964
56
Hadda
,
V.
,
Kumar
,
R.
,
Khilnani
,
G.C.
,
Kalaivani
,
M.
,
Madan
,
K.
,
Tiwari
,
P.
et al
. (
2018
)
Trends of loss of peripheral muscle thickness on ultrasonography and its relationship with outcomes among patients with sepsis
.
J. Intensive Care
6
, 81 https://doi.org/10.1186/s40560-018-0350-4
57
Weijs
,
P.J.M.
,
Looijaard
,
W.G.P.M.
,
Dekker
,
I.M.
,
Stapel
,
S.N.
,
Girbes
,
A.R.
,
Straaten
,
H.M.O.v.
et al
. (
2014
)
Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients
.
Crit. Care
18
, R12 https://doi.org/10.1186/cc13189
58
Renew
,
J.R.
,
Ratzlaff
,
R.
,
Hernandez-Torres
,
V.
,
Brull
,
S.J.
and
Prielipp
,
R.C
. (
2020
)
Neuromuscular blockade management in the critically Ill patient
.
J. Intensive Care
8
,
37
https://doi.org/10.1186/s40560-020-00455-2
59
Laitano
,
O.
,
Pindado
,
J.
,
Valera
,
I.
,
Spradlin
,
R.A.
,
Murray
,
K.O.
,
Villani
,
K.R.
et al
. (
2021
)
The impact of hindlimb disuse on sepsis-induced myopathy in mice
.
Physiol. Rep.
9
, e14979 https://doi.org/10.14814/phy2.14979
60
Puthucheary
,
Z.
,
Rawal
,
J.
,
Ratnayake
,
G.
,
Harridge
,
S.
,
Montgomery
,
H.
and
Hart
,
N
. (
2012
)
Neuromuscular blockade and skeletal muscle weakness in critically ill patients
Am. J. Respir. Crit. Care Med.
185
,
911
917
https://doi.org/10.1164/rccm.201107-1320OE
61
Atramont
,
A.
,
Lindecker-Cournil
,
V.
,
Rudant
,
J.
,
Tajahmady
,
A.
,
Drewniak
,
N.
,
Fouard
,
A.
et al
. (
2019
)
Association of age with short-term and long-term mortality among patients discharged from intensive care units in France
.
JAMA Netw. Open
2
, e193215 https://doi.org/10.1001/jamanetworkopen.2019.3215
62
van Zanten
,
A.R.H.
,
De Waele
,
E.
and
Wischmeyer
,
P.E
. (
2019
)
Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases
.
Crit. Care
23
, 368 https://doi.org/10.1186/s13054-019-2657-5
63
Dhillon
,
R.J.S.
and
Hasni
,
S
. (
2017
)
Pathogenesis and management of sarcopenia
.
Clin. Geriatr. Med.
33
,
17
26
https://doi.org/10.1016/j.cger.2016.08.002
64
Khalil
,
A.
,
Alamri
,
R.A.
,
Aljabri
,
G.H.
,
Shahat
,
E.A.
,
Almughamsi
,
R.I.
and
Almeshhen
,
W.A
. (
2023
)
A cross-sectional study of the impact of icu-acquired weakness: prevalence, associations, and severity
.
Cureus
15
, e49852 https://doi.org/10.7759/cureus.49852
65
Dannenberg
,
V.C.
,
Rovedder
,
P.M.E.
and
Carvalho
,
P.R.A
. (
2023
)
Long-term functional outcomes of children after critical illnesses: A cohort study
.
Medicina Intensiva (English Edition)
47
,
280
288
https://doi.org/10.1016/j.medine.2022.02.022
66
Lipes
,
J.
,
Mardini
,
L.
and
Jayaraman
,
D
. (
2013
)
Sex and mortality of hospitalized adults after admission to an intensive care unit
.
Am. J. Crit. Care
22
,
314
319
https://doi.org/10.4037/ajcc2013225
67
Yang
,
Z.
,
Wang
,
X.
,
Wang
,
F.
,
Peng
,
Z.
and
Fan
,
Y
. (
2022
)
A systematic review and meta-analysis of risk factors for intensive care unit acquired weakness
.
Medicine (Baltimore)
101
, e31405 https://doi.org/10.1097/MD.0000000000031405
68
Sharshar
,
T.
,
Bastuji-Garin
,
S.
,
De Jonghe
,
B.
,
Stevens
,
R.D.
,
Polito
,
A.
,
Maxime
,
V.
et al
. (
2010
)
Hormonal status and ICU-acquired paresis in critically ill patients
.
Intensive Care Med.
36
,
1318
1326
https://doi.org/10.1007/s00134-010-1840-6
69
Engelhardt
,
L.J.
,
Grunow
,
J.J.
,
Wollersheim
,
T.
,
Carbon
,
N.M.
,
Balzer
,
F.
,
Spranger
,
J.
et al
. (
2022
)
Sex-specific aspects of skeletal muscle metabolism in the clinical context of intensive care unit-acquired weakness
.
J. Clin. Med.
11
, 846 https://doi.org/10.3390/jcm11030846
70
Rosa-Caldwell
,
M.E.
,
Lim
,
S.
,
Haynie
,
W.A.
,
Brown
,
J.L.
,
Deaver
,
J.W.
,
Morena Da Silva
,
F.
et al
. (
2021
)
Female mice may have exacerbated catabolic signalling response compared to male mice during development and progression of disuse atrophy
.
J. Cachexia. Sarcopenia Muscle
12
,
717
730
https://doi.org/10.1002/jcsm.12693
71
Domingues-Faria
,
C.
,
Vasson
,
M.P.
,
Goncalves-Mendes
,
N.
,
Boirie
,
Y.
and
Walrand
,
S
. (
2016
)
Skeletal muscle regeneration and impact of aging and nutrition
.
Ageing Res. Rev.
26
,
22
36
https://doi.org/10.1016/j.arr.2015.12.004
72
Peixoto da Silva
,
S.
,
Santos
,
J.M.O.
,
Costa
,
E.S.M.P.
,
Gil da Costa
,
R.M.
and
Medeiros
,
R
. (
2020
)
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia
.
J. Cachexia. Sarcopenia Muscle
11
,
619
635
https://doi.org/10.1002/jcsm.12528
73
Deutz
,
N.E.P.
,
Bauer
,
J.M.
,
Barazzoni
,
R.
,
Biolo
,
G.
,
Boirie
,
Y.
,
Bosy-Westphal
,
A
. et al
. (
2014
)
Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group
.
Clin. Nutr.
33
,
929
936
https://doi.org/10.1016/j.clnu.2014.04.007
74
Abe
,
R.
,
Shimazui
,
T.
,
Sugo
,
M.
,
Ogawa
,
A.
,
Namekawa
,
M.
,
Kitamura
,
N.
et al
. (
2024
)
Achievement of adequate nutrition contributes to maintaining the skeletal muscle area in patients with sepsis undergoing early mobilization: a retrospective observational study
.
BMC Nutr.
10
, 32 https://doi.org/10.1186/s40795-024-00846-w
75
Smith
,
L.O.
,
Vest
,
M.T.
,
Rovner
,
A.J.
,
Caplan
,
R.J.
,
Trabulsi
,
J.C.
,
Patel
,
J.B.
et al
. (
2024
)
Malnutrition and pectoralis muscle index in medical intensive care unit patients: a matched cohort study
.
JPEN J. Parenter. Enteral Nutr.
48
,
300
307
https://doi.org/10.1002/jpen.2610
76
Chapple
,
L.A.S.
,
Kouw
,
I.W.K.
,
Summers
,
M.J.
,
Weinel
,
L.M.
,
Gluck
,
S.
,
Raith
,
E.
et al
. (
2022
)
Muscle protein synthesis after protein administration in critical illness
.
Am. J. Respir. Crit. Care Med.
206
,
740
749
https://doi.org/10.1164/rccm.202112-2780OC
77
Banwell
,
B.L.
,
Mildner
,
R.J.
,
Hassall
,
A.C.
,
Becker
,
L.E.
,
Vajsar
,
J.
and
Shemie
,
S.D
. (
2003
)
Muscle weakness in critically ill children
.
Neurology (ECronicon).
61
,
1779
1782
https://doi.org/10.1212/01.wnl.0000098886.90030.67
78
Field-Ridley
,
A.
,
Dharmar
,
M.
,
Steinhorn
,
D.
,
McDonald
,
C.
and
Marcin
,
J.P
. (
2016
)
ICU-acquired weakness is associated with differences in clinical outcomes in critically ill children*
.
Pediatr. Crit. Care Med.
17
,
53
57
https://doi.org/10.1097/PCC.0000000000000538
79
Johnson
,
R.W.
,
Ng
,
K.W.P.
,
Dietz
,
A.R.
,
Hartman
,
M.E.
,
Baty
,
J.D.
,
Hasan
,
N.
et al
. (
2018
)
Muscle atrophy in mechanically-ventilated critically ill children
.
PLoS ONE
13
, e0207720 https://doi.org/10.1371/journal.pone.0207720
80
Ong
,
C.
,
Lee
,
J.H.
and
Puthucheary
,
Z.A
. (
2021
)
Narrative review of muscle weakness and wasting in pediatric critical illness
.
Pediatr. Med.
4
,
13
https://doi.org/10.21037/pm-20-83
81
Rousseau
,
A.F.
,
Prescott
,
H.C.
,
Brett
,
S.J.
,
Weiss
,
B.
,
Azoulay
,
E.
,
Creteur
,
J.
et al
. (
2021
)
Long-term outcomes after critical illness: recent insights
.
Crit. Care
25
, 108 https://doi.org/10.1186/s13054-021-03535-3
82
Meyer-Frießem
,
C.H.
,
Malewicz
,
N.M.
,
Rath
,
S.
,
Ebel
,
M.
,
Kaisler
,
M.
,
Tegenthoff
,
M.
et al
. (
2021
)
Incidence, time course and influence on quality of life of intensive care unit-acquired weakness symptoms in long-term intensive care survivors
.
J. Intensive Care Med.
36
,
1313
1322
https://doi.org/10.1177/0885066620949178
83
Semmler
,
A.
,
Okulla
,
T.
,
Kaiser
,
M.
,
Seifert
,
B.
and
Heneka
,
MT
. (
2013
)
Long-term neuromuscular sequelae of critical illness
.
J. Neurol.
260
,
151
157
https://doi.org/10.1007/s00415-012-6605-4
84
Boelens
,
Y.F.N.
,
Melchers
,
M.
and
van Zanten
,
A.R.H
. (
2022
)
Poor physical recovery after critical illness: incidence, features, risk factors, pathophysiology, and evidence-based therapies
.
Curr. Opin. Crit. Care
28
,
409
416
https://doi.org/10.1097/MCC.0000000000000955
85
Intiso
,
D.
,
Amoruso
,
L.
,
Zarrelli
,
M.
,
Pazienza
,
L.
,
Basciani
,
M.
,
Grimaldi
,
G.
et al
. (
2011
)
Long-term functional outcome and health status of patients with critical illness polyneuromyopathy
.
Acta Neurol. Scand.
123
,
211
219
https://doi.org/10.1111/j.1600-0404.2010.01414.x
86
Wang
,
W.
,
Xu
,
C.
,
Ma
,
X.
,
Zhang
,
X.
and
Xie
,
P
. (
2020
)
Intensive care unit-acquired weakness: a review of recent progress with a look toward the future
.
Front. Med. (Lausanne)
7
, 559789 https://doi.org/10.3389/fmed.2020.559789
87
Wilcox
,
M.E.
and
Ely
,
E.W
. (
2019
)
Challenges in conducting long-term outcomes studies in critical care
.
Curr. Opin. Crit. Care
25
,
473
488
https://doi.org/10.1097/MCC.0000000000000650
88
Lad
,
H.
,
Saumur
,
T.M.
,
Herridge
,
M.S.
,
dos Santos
,
C.C.
,
Mathur
,
S.
,
Batt
,
J.
et al
. (
2020
)
Intensive care unit-acquired weakness: not just another muscle atrophying condition
.
Int. J. Mol. Sci. [Internet]
21
, 7840 https://doi.org/10.3390/ijms21217840
89
Vintrych
,
P.
,
Al-Obeidallah
,
M.
,
Horák
,
J.
,
Chvojka
,
J.
,
Valešová
,
L.
,
Nalos
,
L.
et al
. (
2022
)
Modeling sepsis, with a special focus on large animal models of porcine peritonitis and bacteremia
.
Front. Physiol.
13
, 1094199 https://doi.org/10.3389/fphys.2022.1094199
90
Fleischmann-Struzek
,
C.
,
Mellhammar
,
L.
,
Rose
,
N.
,
Cassini
,
A.
,
Rudd
,
K.E.
,
Schlattmann
,
P.
et al
. (
2020
)
Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis
.
Intensive Care Med.
46
,
1552
1562
https://doi.org/10.1007/s00134-020-06151-x
91
Jansen
,
M.J.
,
Hendriks
,
T.
,
de Man Man
,
B.M.
,
van der Meer
,
J.W.
and
Goris
,
R.J
. (
1999
)
Interleukin 10 Mitigates the Development of the Zymosan-Induced Multiple Organ Dysfunction Syndrome in Mice
.
Cytokine
11
,
713
721
https://doi.org/10.1006/cyto.1998.0476
92
Ruiz
,
S.
,
Vardon-Bounes
,
F.
,
Merlet-Dupuy
,
V.
,
Conil
,
J.M.
,
Buléon
,
M.
,
Fourcade
,
O
, et al
. (
2016
)
Sepsis modeling in mice: ligation length is a major severity factor in cecal ligation and puncture
.
Intensive Care Med. Exp.
4
,
22
https://doi.org/10.1186/s40635-016-0096-z
93
Ward
,
P.A
. (
2012
)
New approaches to the study of sepsis
.
EMBO Mol. Med.
4
,
1234
1243
https://doi.org/10.1002/emmm.201201375
94
Wichterman
,
K.A.
,
Baue
,
A.E.
and
Chaudry
,
I.H
. (
1980
)
Sepsis and septic shock--a review of laboratory models and a proposal
.
J. Surg. Res.
29
,
189
201
https://doi.org/10.1016/0022-4804(80)90037-2
95
Rittirsch
,
D.
,
Huber-Lang
,
M.S.
,
Flierl
,
M.A.
and
Ward
,
PA
. (
2009
)
Immunodesign of experimental sepsis by cecal ligation and puncture
.
Nat. Protoc.
4
,
31
36
https://doi.org/10.1038/nprot.2008.214
96
Dejager
,
L.
,
Pinheiro
,
I.
,
Dejonckheere
,
E.
and
Libert
,
C
. (
2011
)
Cecal Ligation and Puncture: The Gold Standard Model for Polymicrobial Sepsis
.
Trends Microbiol.
19
,
198
208
https://doi.org/10.1016/j.tim.2011.01.001
97
Lang
,
C.H.
,
Lynch
,
C.J.
and
Vary
,
T.C
. (
2010
)
Bcatm deficiency ameliorates endotoxin-induced decrease in muscle protein synthesis and improves survival in septic mice
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
299
,
R935
R944
https://doi.org/10.1152/ajpregu.00297.2010
98
Steiner
,
J.L.
and
Lang
,
C.H
. (
2015
)
Sepsis Attenuates the Anabolic Response to Skeletal Muscle Contraction
.
Shock
43
,
344
351
https://doi.org/10.1097/SHK.0000000000000304
99
Goossens
,
C.
,
Weckx
,
R.
,
Derde
,
S.
,
Helleputte
,
L.
,
Schneidereit
,
D.
,
Haug
,
M
, et al
. (
2021
)
Impact of prolonged sepsis on neural and muscular components of muscle contractions in a mouse model
.
J. Cachexia Sarcopenia Muscle
12
,
443
455
https://doi.org/10.1002/jcsm.12668
100
Zanders
,
L.
,
Kny
,
M.
,
Hahn
,
A.
,
Schmidt
,
S.
,
Wundersitz
,
S.
,
Todiras
,
M
, et al
. (
2022
)
Sepsis induces interleukin 6, Gp130/Jak2/Stat3, and muscle wasting
.
J. Cachexia. Sarcopenia Muscle
13
,
713
727
https://doi.org/10.1002/jcsm.12867
101
Steiner
,
J.L.
,
Pruznak
,
A.M.
,
Deiter
,
G.
,
Navaratnarajah
,
M.
,
Kutzler
,
L.
,
Kimball
,
S.R.
et al
. (
2014
)
Disruption of genes encoding eIF4E binding proteins-1 and -2 does not alter basal or sepsis-induced changes in skeletal muscle protein synthesis in male or female mice
.
PLOS ONE
9
, e99582 https://doi.org/10.1371/journal.pone.0099582
102
Goossens
,
C.
,
Marques
,
M.B.
,
Derde
,
S.
,
Vander Perre
,
S.
,
Dufour
,
T.
,
Thiessen
,
S.E.
et al
. (
2017
)
Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness
.
J. Cachexia. Sarcopenia Muscle
8
,
89
101
https://doi.org/10.1002/jcsm.12131
103
Goossens
,
C.
,
Weckx
,
R.
,
Derde
,
S.
,
Dufour
,
T.
,
Vander Perre
,
S.
,
Pauwels
,
L.
et al
. (
2019
)
Adipose tissue protects against sepsis-induced muscle weakness in mice: from lipolysis to ketones
.
Crit. Care
23
, 236 https://doi.org/10.1186/s13054-019-2506-6
104
Fareed
,
M.U.
,
Evenson
,
A.R.
,
Wei
,
W.
,
Menconi
,
M.
,
Poylin
,
V.
,
Petkova
,
V.
et al
. (
2006
)
Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
290
,
R1589
R1597
https://doi.org/10.1152/ajpregu.00668.2005
105
Hall-Angerås
,
M.
,
Angerås
,
U.
,
Allmen
,
D.
,
Higashiguchi
,
T.
,
Zamir
,
O.
,
Hasselgren
,
P.O
, et al
. (
1991
)
Influence of sepsis in rats on muscle protein turnover in vivo and in tissue incubated under different in vitro conditions
.
Metab. Clin. Exp.
40
,
247
251
https://doi.org/10.1016/0026-0495(91)90105-6
106
Liu
,
H.
,
Pan
,
D.
,
Li
,
P.
,
Wang
,
D.
,
Xia
,
B.
,
Zhang
,
R.
et al
. (
2023
)
Loss of ZBED6 protects against sepsis-induced muscle atrophy by upregulating DOCK3-mediated RAC1/PI3K/AKT signaling pathway in pigs
.
Adv. Sci.
10
, 2302298 https://doi.org/10.1002/advs.202302298
107
Rossignol
,
B.
,
Gueret
,
G.
,
Pennec
,
J.P.
,
Morel
,
J.
,
Giroux-Metges
,
M.A.
,
Talarmin
,
H.
et al
. (
2007
)
Effects of chronic sepsis on the voltage-gated sodium channel in isolated rat muscle fibers
.
Crit. Care Med.
35
,
351
357
https://doi.org/10.1097/01.CCM.0000254335.88023.0E
108
Yan
,
D.
,
Zhang
,
J.
,
Yan
,
W.
,
Song
,
F.
,
Luo
,
X.
,
Miao
,
H.
et al
. (
2024
)
Transcriptome sequencing analysis reveals the molecular mechanism of sepsis-induced muscle atrophy
.
J. Thorac. Dis.
16
,
7751
7770
https://doi.org/10.21037/jtd-24-1665
109
Schmitt
,
R.E.
,
Dasgupta
,
A.
,
Arneson-Wissink
,
P.C.
,
Datta
,
S.
,
Ducharme
,
A.M.
and
Doles
,
J.D
. (
2023
)
Muscle stem cells contribute to long-term tissue repletion following surgical sepsis
.
J. Cachexia. Sarcopenia Muscle
14
,
1424
1440
https://doi.org/10.1002/jcsm.13214
110
Tidball
,
J.G.
,
Flores
,
I.
,
Welc
,
S.S.
,
Wehling-Henricks
,
M.
and
Ochi
,
E
. (
2021
)
Aging of the immune system and impaired muscle regeneration: a failure of immunomodulation of adult myogenesis
.
Exp. Gerontol.
145
,
111200
https://doi.org/10.1016/j.exger.2020.111200
111
Sakr
,
Y.
,
Jaschinski
,
U.
,
Wittebole
,
X.
,
Szakmany
,
T.
,
Lipman
,
J.
,
Ñamendys-Silva
,
S.A.
et al
. (
2018
)
Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit
.
Open Forum Infect. Dis.
5
, ofy313 https://doi.org/10.1093/ofid/ofy313
112
Frick
,
C.G.
,
Fink
,
H.
,
Gordan
,
M.L.
,
Eckel
,
B.
,
Martyn
,
J.A.J.
and
Blobner
,
M
. (
2008
)
Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers
.
Intensive Care Med.
34
,
561
567
https://doi.org/10.1007/s00134-007-0852-3
113
Chapman
,
M.
,
Maiden
,
M.
,
Fraser
,
J.
,
Nash
,
C.
,
Crichton
,
F.
,
Sideris
,
P.
et al
. (
2010
)
An ovine intensive care model of septic shock
.
Crit. Care
14
,
4
https://doi.org/10.1186/cc8236
114
Wilske
,
F.
,
Skorup
,
P.
,
Hanslin
,
K.
,
Janols
,
H.
,
Larsson
,
A.
,
Lipcsey
,
M.
et al
. (
2023
)
Enhanced bacterial clearance in early secondary sepsis in a porcine intensive care model
.
Sci. Rep.
13
, 1964 https://doi.org/10.1038/s41598-023-28880-x
115
Muñoz
,
K.A.
,
Ulrich
,
R.J.
,
Vasan
,
A.K.
,
Sinclair
,
M.
,
Wen
,
P.C.
,
Holmes
,
J.R.
et al
. (
2024
)
A Gram-negative-selective antibiotic that spares the gut microbiome
.
Nature
630
,
429
436
https://doi.org/10.1038/s41586-024-07502-0
116
He
,
X.H.
,
Ouyang
,
D.Y.
and
Xu
,
L.H
. (
2021
) Injection of Escherichia Coli to Induce Sepsis.
In
Sepsis: Methods and Protocols
(
Walker
,
W.E.
, ed),
pp
.
43
51
,
Springer,
New York
. https://doi.org/10.1007/978-1-0716-1488-4_5
117
Cirioni
,
O.
,
Giacometti
,
A.
,
Ghiselli
,
R.
,
Bergnach
,
C.
,
Orlando
,
F.
,
Silvestri
,
C.
et al
. (
2006
)
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria
.
Antimicrob. Agents Chemother.
50
,
1672
1679
https://doi.org/10.1128/AAC.50.5.1672-1679.2006
118
Schrauwen
,
E.
,
Cox
,
E.
and
Houvenaghel
,
A
. (
1988
)
Escherichia coli sepsis and endotoxemia in conscious young pigs
.
Vet. Res. Commun.
12
,
295
303
https://doi.org/10.1007/BF00343248
119
Berhés
,
M.
,
Németh
,
N.
,
Pető
,
K.
,
Deák
,
Á.
,
Hajdú
,
E.
,
Molnár
,
Á.
et al
. (
2019
)
Hemodynamic consequences of intravenously given E. coli suspension: observations in a fulminant sepsis model in pigs, a descriptive case-control study
.
Eur. J. Med. Res.
24
, 11 https://doi.org/10.1186/s40001-019-0372-y
120
Lankadeva
,
Y.R.
,
Peiris
,
R.M.
,
Okazaki
,
N.
,
Birchall
,
I.E.
,
Trask-Marino
,
A.
,
Dornom
,
A.
et al
. (
2021
)
Reversal of the pathophysiological responses to gram-negative sepsis by megadose vitamin C
.
Crit. Care Med.
49
,
e179
e190
https://doi.org/10.1097/CCM.0000000000004770
121
Lagoa
,
C.E.
,
de Figueiredo
,
L.F.
,
Cruz
,
R.J.
Jr
,
Silva
,
E.
and
Rocha e Silva
,
M
. (
2004
)
Effects of volume resuscitation on splanchnic perfusion in canine model of severe sepsis induced by live Escherichia coli infusion
.
Crit. Care
8
, R221 https://doi.org/10.1186/cc2871
122
Chen
,
L.
,
Welty-Wolf
,
K.E.
and
Kraft
,
B.D
. (
2019
)
Nonhuman primate species as models of human bacterial sepsis
.
Lab Anim. (NY)
48
,
57
65
https://doi.org/10.1038/s41684-018-0217-2
123
Voisin
,
L.
,
Breuillé
,
D.
,
Combaret
,
L.
,
Pouyet
,
C.
,
Taillandier
,
D.
,
Aurousseau
,
E.
et al
. (
1996
)
Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+ -activated, and ubiquitin-proteasome proteolytic pathways
.
J. Clin. Invest.
97
,
1610
1617
https://doi.org/10.1172/JCI118586
124
Maňák
,
J.
,
Schreiber
,
M.
,
Matulová
,
H.
,
Šlemrová
,
M.
,
Cerman
,
J.
,
Šitina
,
M.
et al
. (
2003
)
Early Signs of Critical Illness Polyneuropathy in Porcine Sepsis
.
Crit. Care
7 (Suppl 2)
,
086
https://doi.org/10.1186/cc1975
125
Witteveen
,
E.
,
Wieske
,
L.
,
Manders
,
E.
,
Verhamme
,
C.
,
Ottenheijm
,
C.A.C.
,
Schultz
,
M.J
, et al
. (
2019
)
Muscle weakness in a S. pneumoniae sepsis mouse model
.
Ann. Transl. Med.
7
,
9
https://doi.org/10.21037/atm.2018.12.45
126
Buras
,
J.A.
,
Holzmann
,
B.
and
Sitkovsky
,
M
. (
2005
)
Animal models of sepsis: setting the stage
.
Nat. Rev. Drug Discov.
4
,
854
865
https://doi.org/10.1038/nrd1854
127
Starr
,
M.E.
,
Steele
,
A.M.
,
Saito
,
M.
,
Hacker
,
B.J.
,
Evers
,
B.M.
and
Saito
,
H
. (
2014
)
A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis
.
PLOS ONE
9
, e115705 https://doi.org/10.1371/journal.pone.0115705
128
Lang
,
C.H.
,
Bagby
,
G.J.
,
Bornside
,
G.H.
,
Vial
,
L.J.
and
Spitzer
,
J.J
. (
1983
)
Sustained Hypermetabolic Sepsis in Rats: Characterization of the Model
.
J. Surg. Res.
35
,
201
210
https://doi.org/10.1016/S0022-4804(83)80005-5
129
Derive
,
M.
,
Boufenzer
,
A.
,
Bouazza
,
Y.
,
Groubatch
,
F.
,
Alauzet
,
C.
,
Barraud
,
D
, et al
. (
2013
)
Effects of a trem-like transcript 1-derived peptide during hypodynamic septic shock in pigs
.
Shock
39
,
176
182
https://doi.org/10.1097/SHK.0b013e31827bcdfb
130
Nakanishi
,
N.
,
Ono
,
Y.
,
Miyazaki
,
Y.
,
Moriyama
,
N.
,
Fujioka
,
K.
,
Yamashita
,
K
, et al
. (
2022
)
Sepsis causes neutrophil infiltration in muscle leading to muscle atrophy and weakness in mice
.
Front. Immunol.
13
,
950646
https://doi.org/10.3389/fimmu.2022.950646
131
Brealey
,
D.
,
Karyampudi
,
S.
,
Jacques
,
T.S.
,
Novelli
,
M.
,
Stidwill
,
R.
,
Taylor
,
V.
et al
. (
2004
)
Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
286
,
R491
R497
https://doi.org/10.1152/ajpregu.00432.2003
132
Boërio
,
D.
,
Corrêa
,
T.D.
,
Jakob
,
S.M.
,
Ackermann
,
K.A.
,
Bostock
,
H.
and
Z’Graggen
,
WJ
. (
2018
)
Muscle membrane properties in A pig sepsis model: Effect of norepinephrine
.
Muscle Nerve
57
,
808
813
https://doi.org/10.1002/mus.26013
133
Owen
,
A.M.
,
Patel
,
S.P.
,
Smith
,
J.D.
,
Balasuriya
,
B.K.
,
Mori
,
S.F.
,
Hawk
,
G.S.
et al
. (
2019
)
Chronic muscle weakness and mitochondrial dysfunction in the absence of sustained atrophy in a preclinical sepsis model
.
Elife
8
, e49920 https://doi.org/10.7554/eLife.49920
134
Kingren
,
M.S.
,
Keeble
,
A.R.
,
Galvan-Lara
,
A.M.
,
Ogle
,
J.M.
,
Ungvári
,
Z.
,
Clair
,
D.K
, et al
. (
2024
)
Post-sepsis chronic muscle weakness can be prevented by pharmacological protection of mitochondria
.
Mol. Med.
30
,
221
https://doi.org/10.1186/s10020-024-00982-w
135
Atre
,
R.
,
Sharma
,
R.
,
Obukhov
,
A.G.
,
Saqib
,
U.
,
Umar
,
S.
,
Darwhekar
,
G.N
, et al
. (
2024
)
An improved mouse model of sepsis based on intraperitoneal injections of the enriched culture of cecum slurry
.
Life Sci.
345
,
122584
https://doi.org/10.1016/j.lfs.2024.122584
136
Zantl
,
N.
,
Uebe
,
A.
,
Neumann
,
B.
,
Wagner
,
H.
,
Siewert
,
J.R.
,
Holzmann
,
B.
et al
. (
1998
)
Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis
.
Infect. Immun.
66
,
2300
2309
https://doi.org/10.1128/IAI.66.5.2300-2309.1998
137
Utiger
,
J.M.
,
Glas
,
M.
,
Levis
,
A.
,
Prazak
,
J.
and
Haenggi
,
M
. (
2021
)
Description of a rat model of polymicrobial abdominal sepsis mimicking human colon perforation
.
BMC Res. Notes
14
, 14 https://doi.org/10.1186/s13104-020-05438-y
138
Ghanta
,
S.
,
Kwon
,
M.Y.
and
Perrella
,
M.A
. (
2021
) Induction of Sepsis Via Fibrin Clot Implantation.
In
Sepsis: Methods and Protocols
(
Walker
,
W.E.
, ed),
pp
.
17
25
,
Springer US
,
New York
. https://doi.org/10.1007/978-1-0716-1488-4_3
139
Natanson
,
C.
,
Eichenholz
,
P.W.
,
Danner
,
R.L.
,
Eichacker
,
P.Q.
,
Hoffman
,
W.D.
,
Kuo
,
G.C.
et al
. (
1989
)
Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock
.
J. Exp. Med.
169
,
823
832
https://doi.org/10.1084/jem.169.3.823
140
Hermreck
,
A.S.
and
Thal
,
A.P
. (
1969
)
Mechanisms for the high circulatory requirements in sepsis and septic shock
.
Ann. Surg.
170
,
677
695
https://doi.org/10.1097/00000658-196910000-00017
141
Walker
,
H.L.
,
Mason
,
A.D.
Jr
and
Raulston
,
G.L
. (
1964
)
Surface infection with Pseudomonas Aeruginosa
.
Ann. Surg.
160
,
297
305
https://doi.org/10.1097/00000658-196408000-00019
142
LaNoue
,
K.F.
,
Mason
,
A.D.
Jr
and
Daniels
,
JP
. (
1968
)
The impairment of glucogenesis by gram negative infection
.
Metab. Clin. Exp.
17
,
606
611
https://doi.org/10.1016/0026-0495(68)90019-x
143
Minneci
,
P.C.
,
Deans
,
K.J.
,
Hansen
,
B.
,
Parent
,
C.
,
Romines
,
C.
,
Gonzales
,
D.A.
et al
. (
2007
)
A canine model of septic shock: balancing animal welfare and scientific relevance
.
Am. J. Physiol. Heart Circ. Physiol.
293
,
H2487
H2500
https://doi.org/10.1152/ajpheart.00589.2007
144
Kumar
,
V
. (
2020
)
Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets
.
Int. Immunopharmacol
89 (Pt B)
,
107087
https://doi.org/10.1016/j.intimp.2020.107087
145
Boeno
,
F.P.
,
Muller
,
D.C.
,
Aldakkan
,
A.
,
Li
,
Z.
,
Reis
,
G.
,
Barton
,
E.R.
et al
. (
2024
)
A preclinical model of sepsis-induced myopathy with disuse in mice
.
J. Vis. Exp.
2024
,
208
https://doi.org/10.3791/66685
146
Li
,
X.
,
Sun
,
B.
,
Li
,
J.
,
Ye
,
W.
,
Li
,
M.
,
Guan
,
F.
et al
. (
2023
)
Sepsis leads to impaired mitochondrial calcium uptake and skeletal muscle weakness by reducing the Micu1:Mcu protein ratio
.
Shock
60
,
698
706
https://doi.org/10.1097/SHK.0000000000002221
147
Lee
,
S.J.
,
Gharbi
,
A.
,
Shin
,
J.E.
,
Jung
,
I.D.
and
Park
,
Y.M
. (
2021
)
Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis
.
Biochem. Biophys. Res. Commun.
543
,
1
7
https://doi.org/10.1016/j.bbrc.2021.01.030
148
Breuille
,
D.
,
Voisin
,
L.
,
Contrepois
,
M.
,
Arnal
,
M.
,
Rose
,
F.
and
Obled
,
C
. (
1999
)
A sustained rat model for studying the long-lasting catabolic state of sepsis
.
Infect. Immun.
67
,
1079
1085
https://doi.org/10.1128/IAI.67.3.1079-1085.1999
149
Ten Have
,
G.A.M.
,
Deutz
,
R.C.I.
,
Engelen
,
M.
,
Wolfe
,
R.R.
and
Deutz
,
N.E.P
. (
2018
)
Characteristics of a Pseudomonas aeruginosa induced porcine sepsis model for multi-organ metabolic flux measurements
.
Lab. Anim.
52
,
163
175
https://doi.org/10.1177/0023677217718003
150
Ono
,
Y.
,
Maejima
,
Y.
,
Saito
,
M.
,
Sakamoto
,
K.
,
Horita
,
S.
,
Shimomura
,
K.
et al
. (
2020
)
TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice
.
Sci. Rep.
10
, 694 https://doi.org/10.1038/s41598-020-57714-3
151
Ham
,
D.J.
,
Caldow
,
M.K.
,
Chhen
,
V.
,
Chee
,
A.
,
Wang
,
X.
,
Proud
,
C.G.
et al
. (
2016
)
Glycine restores the anabolic response to leucine in a mouse model of acute inflammation
.
Am. J. Physiol. Endocrinol. Metab.
310
,
E970
E981
https://doi.org/10.1152/ajpendo.00468.2015
152
Wang
,
Y.
,
Chu
,
Y.
,
Dai
,
H.
,
Zheng
,
Y.
,
Chen
,
R.
,
Zhou
,
C.
et al
. (
2024
)
Protective role of pretreatment with Anisodamine against sepsis-induced diaphragm atrophy via inhibiting JAK2/STAT3 pathway
.
Int. Immunopharmacol.
133
,
112133
https://doi.org/10.1016/j.intimp.2024.112133
153
Fang
,
W.Y.
,
Tseng
,
Y.T.
,
Lee
,
T.Y.
,
Fu
,
Y.C.
,
Chang
,
W.H.
,
Lo
,
W.W.
et al
. (
2021
)
Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway
.
Br. J. Pharmacol.
178
,
2998
3016
https://doi.org/10.1111/bph.15472
154
Bivona
,
J.J.
3rd
,
Crymble
,
H.M.
,
Guigni
,
B.A.
,
Stapleton
,
R.D.
,
Files
,
D.C.
,
Toth
,
M.J.
et al
. (
2021
)
Macrophages augment the skeletal muscle proinflammatory response through TNFα following LPS-induced acute lung injury
.
FASEB J.
35
, e21462 https://doi.org/10.1096/fj.202002275RR
155
Bivona Iii
,
J.J.
,
Mank
,
M.M.
,
Stapleton
,
R.D.
,
Files
,
D.C.
,
Toth
,
M.J.
and
Poynter
,
M.E
. (
2022
)
Skeletal muscle myofibers directly contribute to lps-induced systemic inflammatory tone
.
Front. Pharmacol.
13
, 917917 https://doi.org/10.3389/fphar.2022.917917
156
Valentine
,
R.J.
,
Jefferson
,
M.A.
,
Kohut
,
M.L.
and
Eo
,
H
. (
2018
)
Imoxin attenuates LPS-induced inflammation and MuRF1 expression in mouse skeletal muscle
.
Physiol. Rep.
6
, e13941 https://doi.org/10.14814/phy2.13941
157
Supinski
,
G.S.
,
Vanags
,
J.
and
Callahan
,
LA
. (
2009
)
Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction
.
Am. J. Physiol. Lung Cell Mol. Physiol.
296
,
L994
L1001
https://doi.org/10.1152/ajplung.90404.2008
158
Wan
,
J.
,
Chen
,
D.
,
Yu
,
B.
,
Luo
,
Y.
,
Mao
,
X.
,
Zheng
,
P.
et al
. (
2017
)
Leucine Protects Against Skeletal Muscle Atrophy in Lipopolysaccharide-Challenged Rats
.
J. Med. Food
20
,
93
101
https://doi.org/10.1089/jmf.2016.3759
159
Ozkok
,
E.
,
Yorulmaz
,
H.
,
Ates
,
G.
,
Aksu
,
A.
,
Balkis
,
N.
,
Şahin
,
Ö.
et al
. (
2016
)
Amelioration of energy metabolism by melatonin in skeletal muscle of rats with LPS induced endotoxemia
.
Physiol. Res.
65
,
833
842
https://doi.org/10.33549/physiolres.933282
160
Lang
,
C.H.
,
Spolarics
,
Z.
,
Ottlakan
,
A.
and
Spitzer
,
J.J
. (
1993
)
Effect of high-dose endotoxin on glucose production and utilization
.
Metab. Clin. Exp.
42
,
1351
1358
https://doi.org/10.1016/0026-0495(93)90137-d
161
Alamdari
,
N.
,
Constantin-Teodosiu
,
D.
,
Murton
,
A.J.
,
Gardiner
,
S.M.
,
Bennett
,
T.
,
Layfield
,
R.
et al
. (
2008
)
Temporal changes in the involvement of pyruvate dehydrogenase complex in muscle lactate accumulation during lipopolysaccharide infusion in rats
.
J. Physiol.
586
,
1767
1775
https://doi.org/10.1113/jphysiol.2007.149625
162
Verhees
,
K.J.
,
Pansters
,
N.A.
,
Baarsma
,
H.A.
,
Remels
,
A.H.
,
Haegens
,
A.
,
de Theije
,
C.C
, et al
. (
2013
)
Pharmacological inhibition of Gsk-3 in a guinea pig model of lps-induced pulmonary inflammation: Ii
.
Effects on Skeletal Muscle Atrophy. Respir. Res.
14
,
117
https://doi.org/10.1186/1465-9921-14-117
163
Zhang
,
J.
,
Fu
,
S.L.
,
Liu
,
Y.
,
Liu
,
Y.L.
and
Wang
,
W.J
. (
2015
)
Analysis of microRNA expression profiles in weaned pig skeletal muscle after lipopolysaccharide challenge
.
Int. J. Mol. Sci.
16
,
22438
22455
https://doi.org/10.3390/ijms160922438
164
Ochala
,
J.
,
Ahlbeck
,
K.
,
Radell
,
P.J.
,
Eriksson
,
L.I.
and
Larsson
,
L
. (
2011
)
Factors underlying the early limb muscle weakness in acute quadriplegic myopathy using an experimental ICU porcine model
.
PLoS ONE
6
, e20876 https://doi.org/10.1371/journal.pone.0020876
165
Kang
,
P.
,
Wang
,
X.
,
Wu
,
H.
,
Zhu
,
H.
,
Hou
,
Y.
,
Wang
,
L.
et al
. (
2017
)
Glutamate alleviates muscle protein loss by modulating TLR4, NODs, Akt/FOXO and mTOR signaling pathways in LPS-challenged piglets
.
PLOS ONE
12
, e0182246 https://doi.org/10.1371/journal.pone.0182246
166
Aare
,
S.
,
Radell
,
P.
,
Eriksson
,
L.I.
,
Chen
,
Y.W.
,
Hoffman
,
E.P.
and
Larsson
,
L
. (
2012
)
Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model
.
Physiol. Genomics
44
,
865
877
https://doi.org/10.1152/physiolgenomics.00031.2012
167
Hill
,
N.E.
,
Saeed
,
S.
,
Phadke
,
R.
,
Ellis
,
M.J.
,
Chambers
,
D.
,
Wilson
,
D.R
, et al
. (
2015
)
Detailed characterization of a long-term rodent model of critical illness and recovery
.
Crit. Care Med.
43
,
e84
e96
https://doi.org/10.1097/CCM.0000000000000854
168
Rooyackers
,
O.E.
,
Saris
,
W.H.
,
Soeters
,
P.B.
and
Wagenmakers
,
AJ
. (
1994
)
Prolonged changes in protein and amino acid metabolism after zymosan treatment in Rats
.
Clin. Sci. (Lond)
87
,
619
626
https://doi.org/10.1042/cs0870619
169
Yamada
,
T.
,
Himori
,
K.
,
Tatebayashi
,
D.
,
Yamada
,
R.
,
Ashida
,
Y.
,
Imai
,
T
, et al
. (
2018
)
Electrical stimulation prevents preferential skeletal muscle myosin loss in steroid-denervation rats
.
Front. Physiol.
9
,
1111
https://doi.org/10.3389/fphys.2018.01111
170
Massa
,
R.
,
Carpenter
,
S.
,
Holland
,
P.
and
Karpati
,
G
. (
1992
)
Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation
.
Muscle Nerve
15
,
1290
1298
https://doi.org/10.1002/mus.880151112
171
Rich
,
M.M.
and
Pinter
,
M.J
. (
2003
)
Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy
.
J. Physiol.
547 (Pt 2)
,
555
566
https://doi.org/10.1113/jphysiol.2002.035188
172
Corpeno Kalamgi
,
R.
,
Salah
,
H.
,
Gastaldello
,
S.
,
Martinez-Redondo
,
V.
,
Ruas
,
J.L.
,
Fury
,
W.
et al
. (
2016
)
Mechano-signalling pathways in an experimental intensive critical illness myopathy model
.
J. Physiol.
594
,
4371
4388
https://doi.org/10.1113/JP271973
173
Padfield
,
K.E.
,
Astrakas
,
L.G.
,
Zhang
,
Q.
,
Gopalan
,
S.
,
Dai
,
G.
,
Mindrinos
,
M.N.
et al
. (
2005
)
Burn injury causes mitochondrial dysfunction in skeletal muscle
.
Proc. Natl. Acad. Sci.
102
,
5368
5373
https://doi.org/10.1073/pnas.0501211102
174
Ono
,
Y.
,
Saito
,
M.
,
Sakamoto
,
K.
,
Maejima
,
Y.
,
Misaka
,
S.
,
Shimomura
,
K.
et al
. (
2022
)
C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice
.
Front. Pharmacol.
13
, 1031906 https://doi.org/10.3389/fphar.2022.1031906
175
Wu
,
X.
,
Wolf
,
S.E.
and
Walters
,
T.J
. (
2010
)
Muscle contractile properties in severely burned rats
.
Burns
36
,
905
911
https://doi.org/10.1016/j.burns.2010.02.003
176
Song
,
J.
,
Chowdhury
,
I.H.
,
Choudhuri
,
S.
,
Ayadi
,
A.E.I.
,
Rios
,
L.E.
,
Wolf
,
S.E.
et al
. (
2023
)
Acute muscle mass loss was alleviated with HMGB1 neutralizing antibody treatment in severe burned rats
.
Sci. Rep.
13
, 10250 https://doi.org/10.1038/s41598-023-37476-4
177
Dombrecht
,
D.
,
Van Daele
,
U.
,
Van Asbroeck
,
B.
,
Schieffelers
,
D.R.
,
Guns
,
P.J.
and
van Breda
,
E
. (
2023
)
Skeletal muscle wasting after burn is regulated by a decrease in anabolic signaling in the early flow phase
.
Burns
49
,
1574
1584
https://doi.org/10.1016/j.burns.2023.08.011
178
Wu
,
K.C.
,
Lin
,
H.W.
,
Chu
,
P.C.
,
Li
,
C.I.
,
Kao
,
H.H.
,
Lin
,
C.H.
et al
. (
2023
)
A non-invasive mouse model that recapitulates disuse-induced muscle atrophy in immobilized patients
.
Sci. Rep.
13
, 22201 https://doi.org/10.1038/s41598-023-49732-8
179
Shimkus
,
K.L.
,
Jefferson
,
L.S.
,
Gordon
,
B.S.
and
Kimball
,
S.R
. (
2018
)
Repressors of mTORC1 act to blunt the anabolic response to feeding in the soleus muscle of a cast-immobilized mouse hindlimb
.
Physiol. Rep.
6
, e13891 https://doi.org/10.14814/phy2.13891
180
Caron
,
A.Z.
,
Drouin
,
G.
,
Desrosiers
,
J.
,
Trensz
,
F.
and
Grenier
,
G
. (
2009
)
A novel hindlimb immobilization procedure for studying skeletal muscle atrophy and recovery in mouse
.
J. Appl. Physiol.
106
,
2049
2059
https://doi.org/10.1152/japplphysiol.91505.2008
181
Thompson
,
J.L.M.
,
West
,
D.W.D.
,
Doering
,
T.M.
,
Budiono
,
B.P.
,
Lessard
,
S.J.
,
Koch
,
L.G.
et al
. (
2022
)
Effect of short-term hindlimb immobilization on skeletal muscle atrophy and the transcriptome in a low compared with high responder to endurance training model
.
PLoS ONE
17
, e0261723 https://doi.org/10.1371/journal.pone.0261723
182
Booth
,
FW
. (
1977
)
Time course of muscular atrophy during immobilization of hindlimbs in rats
.
J. Appl. Physiol.
43
,
656
661
https://doi.org/10.1152/jappl.1977.43.4.656
183
van Hees
,
H.W.H.
,
Schellekens
,
W.J.M.
,
Linkels
,
M.
,
Leenders
,
F.
,
Zoll
,
J.
,
Donders
,
R
, et al
. (
2011
)
Plasma from septic shock patients induces loss of muscle protein
.
Crit. Care
15
, R233 https://doi.org/10.1186/cc10475
184
Tardif
,
N.
,
Polia
,
F.
,
Tjäder
,
I.
,
Gustafsson
,
T.
and
Rooyackers
,
O
. (
2019
)
Autophagy flux in critical illness, a translational approach
.
Sci. Rep.
9
, 10762 https://doi.org/10.1038/s41598-019-45500-9
185
Pahil
,
K.S.
,
Gilman
,
M.S.A.
,
Baidin
,
V.
,
Clairfeuille
,
T.
,
Mattei
,
P.
,
Bieniossek
,
C.
et al
. (
2024
)
A new antibiotic traps lipopolysaccharide in its intermembrane transporter
.
Nature
625
,
572
577
https://doi.org/10.1038/s41586-023-06799-7
186
van Langevelde
,
P.
,
Kwappenberg
,
K.M.
,
Groeneveld
,
P.H.
,
Mattie
,
H.
and
van Dissel
,
J.T
. (
1998
)
Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS
.
Antimicrob. Agents Chemother.
42
,
739
743
https://doi.org/10.1128/AAC.42.4.739
187
Rezania
,
S.
,
Amirmozaffari
,
N.
,
Tabarraei
,
B.
,
Jeddi-Tehrani
,
M.
,
Zarei
,
O.
,
Alizadeh
,
R.
et al
. (
2011
)
Extraction, purification and characterization of lipopolysaccharide from Escherichia coli and Salmonella typhi
.
Avicenna J. Med. Biotechnol.
3
,
3
9
188
Grube
,
B.J.
,
Cochane
,
C.G.
,
Ye
,
R.D.
,
Green
,
C.E.
,
McPhail
,
M.E.
,
Ulevitch
,
R.J.
et al
. (
1994
)
Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells
.
J. Biol. Chem.
269
,
8477
8482
189
Ciesielska
,
A.
,
Matyjek
,
M.
and
Kwiatkowska
,
K
. (
2021
)
TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling
.
Cell. Mol. Life Sci.
78
,
1233
1261
https://doi.org/10.1007/s00018-020-03656-y
190
Zhang
,
H.J.
,
Wang
,
B.H.
,
Wang
,
X.
,
Huang
,
C.P.
,
Xu
,
S.M.
,
Wang
,
J.L.
et al
. (
2024
)
Handelin alleviates cachexia- and aging-induced skeletal muscle atrophy by improving protein homeostasis and inhibiting inflammation
.
J. Cachexia. Sarcopenia Muscle
15
,
173
188
https://doi.org/10.1002/jcsm.13381
191
Gusev
,
E.
,
Liang
,
F.
,
Bhattarai
,
S.
,
Broering
,
F.E.
,
Leduc-Gaudet
,
J.P.
,
Hussain
,
S.N.
et al
. (
2022
)
Characterization of skeletal muscle wasting pathways in diaphragm and limb muscles of cystic fibrosis mice
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
322
,
R551
R561
https://doi.org/10.1152/ajpregu.00225.2021
192
Orellana
,
R.A.
,
Wilson
,
F.A.
,
Gazzaneo
,
M.C.
,
Suryawan
,
A.
,
Davis
,
T.A.
and
Nguyen
,
H.V
. (
2011
)
Sepsis and development impede muscle protein synthesis in neonatal pigs by different ribosomal mechanisms
.
Pediatr. Res.
69
,
473
478
https://doi.org/10.1203/PDR.0b013e3182176da1
193
Orellana
,
R.A.
,
Kimball
,
S.R.
,
Nguyen
,
H.V.
,
Bush
,
J.A.
,
Suryawan
,
A.
,
Thivierge
,
M.C.
et al
. (
2004
)
Regulation of muscle protein synthesis in neonatal pigs during prolonged endotoxemia
.
Pediatr. Res.
55
,
442
449
https://doi.org/10.1203/01.PDR.0000110526.02282.F3
194
Goris
,
R.J.
,
Boekholtz
,
W.K.
,
van Bebber
,
I.P.
,
Nuytinck
,
J.K.
and
Schillings
,
P.H
. (
1986
)
Multiple-organ failure and sepsis without bacteria. An experimental model
.
Arch. Surg.
121
,
897
901
https://doi.org/10.1001/archsurg.1986.01400080039006
195
Sato
,
M.
,
Sano
,
H.
,
Iwaki
,
D.
,
Kudo
,
K.
,
Konishi
,
M.
,
Takahashi
,
H.
et al
. (
2003
)
Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A
.
J. Immunol.
171
,
417
425
https://doi.org/10.4049/jimmunol.171.1.417
196
Volman
,
T.J.
,
Hendriks
,
T.
and
Goris
,
R.J
. (
2005
)
Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome
.
Shock
23
,
291
297
https://doi.org/10.1097/01.shk.0000155350.95435.28
197
Mullaly
,
S.C.
and
Kubes
,
P
. (
2007
)
Mast cell-expressed complement receptor, Not Tlr2, is the main detector of zymosan in peritonitis
.
Eur. J. Immunol.
37
,
224
234
https://doi.org/10.1002/eji.200636405
198
Rooyackers
,
O.E.
,
Gijsen
,
A.P.
,
Saris
,
W.H.
,
Soeters
,
P.B.
and
Wagenmakers
,
AJ
. (
1996
)
Derangement in aerobic and anaerobic energy metabolism in skeletal muscle of critically ill and recovering rats
.
Biochim. Biophys. Acta
1315
,
55
60
https://doi.org/10.1016/0925-4439(95)00103-4
199
Rooyackers
,
O.E.
,
Hesselink
,
M.K.
and
Wagenmakers
,
A.J
. (
1997
)
Contraction failure of skeletal muscle of rats recovering from critical illness
.
Clin. Sci. (Lond)
92
,
189
195
https://doi.org/10.1042/cs0920189
200
Rooyackers
,
O.E.
,
Kersten
,
A.H.
and
Wagenmakers
,
A.J
. (
1996
)
Mitochondrial protein content and in vivo synthesis rates in skeletal muscle from critically ill rats
.
Clin. Sci. (Lond)
91
,
475
481
https://doi.org/10.1042/cs0910475
201
Rooyackers
,
O.E.
,
Senden
,
J.M.
,
Soeters
,
P.B.
,
Saris
,
W.H.
and
Wagenmakers
,
A.J
. (
1995
)
Prolonged activation of the branched-chain alpha-keto acid dehydrogenase complex in muscle of zymosan treated rats
.
Eur. J. Clin. Invest.
25
,
548
552
https://doi.org/10.1111/j.1365-2362.1995.tb01744.x
202
Rooyackers
,
O.E.
,
Soeters
,
P.B.
,
Saris
,
W.H.
and
Wagenmakers
,
A.J
. (
1995
)
Effect of an enterally administered glutamine-rich protein on the catabolic response to a zymosan challenge in rats
.
Clin. Nutr.
14
,
105
115
https://doi.org/10.1016/s0261-5614(95)80030-1
203
Hill
,
N.E.
,
Murphy
,
K.G.
,
Saeed
,
S.
,
Phadke
,
R.
,
Chambers
,
D.
,
Wilson
,
D.R
, et al
. (
2017
)
Impact of ghrelin on body composition and muscle function in a long-term rodent model of critical illness
.
PLoS ONE
12
, e0182659 https://doi.org/10.1371/journal.pone.0182659
204
Minnaard
,
R.
,
Drost
,
M.R.
,
Wagenmakers
,
A.J.
,
van Kranenburg
,
G.P.
,
Kuipers
,
H.
and
Hesselink
,
M.K
. (
2005
)
Skeletal muscle wasting and contractile performance in septic rats
.
Muscle Nerve
31
,
339
348
https://doi.org/10.1002/mus.20268
205
Minnaard
,
R.
,
Wagenmakers
,
A.J.
,
Combaret
,
L.
,
Attaix
,
D.
,
Drost
,
M.R.
,
Kranenburg
,
G.P
, et al
. (
2005
)
Ubiquitin-proteasome-dependent proteolytic activity remains elevated after zymosan-induced sepsis in rats while muscle mass recovers
.
Int. J. Biochem. Cell Biol.
37
,
2217
2225
https://doi.org/10.1016/j.biocel.2005.05.002
206
Preau
,
S.
,
Ambler
,
M.
,
Sigurta
,
A.
,
Kleyman
,
A.
,
Dyson
,
A.
,
Hill
,
N.E
, et al
. (
2019
)
Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
316
,
R584
R593
https://doi.org/10.1152/ajpregu.00221.2018
207
Leduc-Gaudet
,
J.P.
,
Miguez
,
K.
,
Cefis
,
M.
,
Faitg
,
J.
,
Moamer
,
A.
,
Chaffer
,
T.J.
et al
. (
2023
)
Autophagy ablation in skeletal muscles worsens sepsis-induced muscle wasting, impairs whole-body metabolism, and decreases survival
.
iScience
26
, 107475 https://doi.org/10.1016/j.isci.2023.107475
208
Pierre
,
A.
,
Bourel
,
C.
,
Favory
,
R.
,
Brassart
,
B.
,
Wallet
,
F.
,
Daussin
,
F.N.
et al
. (
2023
)
Sepsis-like Energy Deficit Is Not Sufficient to Induce Early Muscle Fiber Atrophy and Mitochondrial Dysfunction in a Murine Sepsis Model
.
Biology (Basel)
12
, 529 https://doi.org/10.3390/biology12040529
209
Oh
,
T.S.
,
Zabalawi
,
M.
,
Jain
,
S.
,
Long
,
D.
,
Stacpoole
,
P.W.
,
McCall
,
C.E.
et al
. (
2022
)
Dichloroacetate improves systemic energy balance and feeding behavior during sepsis
.
JCI Insight
7
, e153944 https://doi.org/10.1172/jci.insight.153944
210
Knuth
,
C.M.
,
Auger
,
C.
and
Jeschke
,
M.G
. (
2021
)
Burn-induced hypermetabolism and skeletal muscle dysfunction
.
Am. J. Physiol., Cell Physiol.
321
,
C58
C71
https://doi.org/10.1152/ajpcell.00106.2021
211
Derde
,
S.
,
Vanhorebeek
,
I.
,
Ververs
,
E.J.
,
Vanhees
,
I.
,
Darras
,
V.M.
,
Van Herck
,
E.
et al
. (
2010
)
Increasing intravenous glucose load in the presence of normoglycemia: effect on outcome and metabolism in critically ill rabbits
.
Crit. Care Med.
38
,
602
611
https://doi.org/10.1097/CCM.0b013e3181c03f65
212
Addinsall
,
A.B.
,
Cacciani
,
N.
,
Backéus
,
A.
,
Hedström
,
Y.
,
Shevchenko
,
G.
,
Bergquist
,
J.
et al
. (
2022
)
Electrical stimulated GLUT4 signalling attenuates critical illness-associated muscle wasting
.
J. Cachexia. Sarcopenia Muscle
13
,
2162
2174
https://doi.org/10.1002/jcsm.12978
213
Llano-Diez
,
M.
,
Cheng
,
A.J.
,
Jonsson
,
W.
,
Ivarsson
,
N.
,
Westerblad
,
H.
,
Sun
,
V.
et al
. (
2016
)
Impaired Ca(2+) release contributes to muscle weakness in a rat model of critical illness myopathy
.
Crit. Care
20
, 254 https://doi.org/10.1186/s13054-016-1417-z
214
Ham
,
D.J.
,
Kennedy
,
T.L.
,
Caldow
,
M.K.
,
Chee
,
A.
,
Lynch
,
G.S.
and
Koopman
,
R
. (
2015
)
Citrulline does not prevent skeletal muscle wasting or weakness in limb-casted mice
.
J. Nutr.
145
,
900
906
https://doi.org/10.3945/jn.114.203737
215
Boeno
,
F.P.
,
Roesch
,
L.F.W.
,
Efron
,
P.A.
and
Laitano
,
O
. (
2024
)
Proteomic Profiling of Hindlimb Skeletal Muscle Disuse in a Murine Model of Sepsis
.
Crit. Care Explor.
6
, e1144 https://doi.org/10.1097/CCE.0000000000001144
216
Fitts
,
R.H.
,
Metzger
,
J.M.
,
Riley
,
D.A.
and
Unsworth
,
B.R
. (
1986
)
Models of disuse: a comparison of hindlimb suspension and immobilization
.
J. Appl. Physiol.
60
,
1946
1953
https://doi.org/10.1152/jappl.1986.60.6.1946
217
Jiang
,
Y.
,
Wei
,
Q.
,
Liu
,
W.
,
Chen
,
Q.
,
Chen
,
X.
,
Yuan
,
Z.
et al
. (
2022
)
Exploring the Muscle Metabolomics in the Mouse Model of Sepsis-Induced Acquired Weakness
.
Evid. Based Complement. Alternat. Med.
2022
, 6908488 https://doi.org/10.1155/2022/6908488
218
Ono
,
Y.
and
Sakamoto
,
K
. (
2017
)
Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-A
.
PLoS ONE
12
, e0182040 https://doi.org/10.1371/journal.pone.0182040
219
Rocheteau
,
P.
,
Chatre
,
L.
,
Briand
,
D.
,
Mebarki
,
M.
,
Jouvion
,
G.
,
Bardon
,
J.
et al
. (
2015
)
Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy
.
Nat. Commun.
6
, 10145 https://doi.org/10.1038/ncomms10145
220
Mills
,
R.J.
,
Parker
,
B.L.
,
Monnot
,
P.
,
Needham
,
E.J.
,
Vivien
,
C.J.
,
Ferguson
,
C
, et al
. (
2019
)
Development of a human skeletal micro muscle platform with pacing capabilities
.
Biomaterials
198
,
217
227
https://doi.org/10.1016/j.biomaterials.2018.11.030
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).